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ABSTRACT 
Cannabis has been around for thousands of years and has been used recreationally, 
medicinally, and for fiber. Over 400 compounds have been isolated from Cannabis sativa with 
approximately 100 being cannabinoids. Of those 100 compounds, Δ9-THC has been determined 
as the primary constituent, which is also responsible for the psychoactivity associated with 
Cannabis. Along with Δ9-THC, cannabidiol has been studied in depth for its therapeutic effects. 
This has currently been the focus of many researchers since cannabidiol does not cause 
psychotropic effects. 
Cannabinoid receptors belong to the large superfamily of G protein-coupled receptors 
(GPCRs). Approximately 30% of marketed drugs target GPCRs, therefore, furthering the 
importance of targeting the cannabinoid receptors to treat a variety of conditions such as pain, 
neurodegeneration, appetite, immune function, anxiety, cancer, and many others. Developing in 
vitro bioassays to determine binding and functional activity of compounds has the ability to lead 
researchers to develop a safe and effective drug that may target the cannabinoid receptors. The 
objective is to display the therapeutic effects associated with Cannabis while eliminating the 
unwanted effects such as psychoactivity and anxiety.   
Using radioligand binding and functional bioassays, a structure-activity relationship 
(SAR) for major and minor cannabinoids was developed. The importance of SAR is to determine 
specific characteristics of a compound that allow it to bind to a specific receptor. The objective  
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with cannabinoid receptors is to selectively target CB2 receptors in order to avoid psychoactivity 
associated with CB1 receptor stimulation.  Altering a compound structure based on SARs has the 
potential to become a lead for a novel therapeutic agent.  
These radioligand assays were also used to evaluate the volatile oil of high potency 
Cannabis sativa. The volatile oil was subjected to bioassay-guided fractionation affording seven 
different fractions, three of which were active. Of the three, only one fraction did not contain Δ9-
THC. The ability of the volatile oil fraction that lacks Δ9-THC to activate the cannabinoid 
receptors may exist due to synergistic relationships between the minor and major components.  
The research presented in this dissertation confirms that compounds from Cannabis sativa 
have the potential for becoming novel therapeutic drugs that specifically target the cannabinoid 
receptors in order to treat a variety of diseases.  
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CHAPTER I 
INTRODUCTION 
A. Cannabis 
Marijuana, also known as Cannabis, is defined as any preparation of the Cannabis plant 
used to elicit psychoactive effects whether it is recreational or medicinal. According to the 2004 
World Drug Report, 3.7% of the population 15-64 years of age consumed marijuana from 2001-
2003 (2004). The use of marijuana is associated with numerous pharmacological effects; most, 
but not all may be attributed to Δ9-tetrahydrocannabinol (Δ9-THC, 1) (Figure 1.1).  
 
Figure 1.1. The chemical structure of Δ9-tetrahydrocannabinol. 
The combination of 1 and other compounds from Cannabis, such as cannabidiol (CBD, 
2), may exhibit specific pharmacological effects. Since Δ9-THC is primarily responsible for the 
psychoactive effects of Cannabis, scientists have arned how to genetically increase the 
concentration of 1 within plants to produce a stronger “high.” Since 1980, the concentration of 1 
within marijuana has increased from less than 1.5% to approximately 20% (ElSohly 2000).  
Cannabis use has been around for thousands of years and is not only associated with 
recreational or medicinal use, but it is also used for fiber and seeds. Cannabis produces a durable 
fiber, called hemp, for the manufacturing of rope and fabric. Along with the production of hemp, 
O
OH
!9"tetrahydrocannabinol, 1
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the seeds of Cannabis are rich in B vitamins, protein, and amino acids. The use of Cannabis dates 
back to around 200 BC when the Chinese invented hemp paper. Today, this plant serves as a 
recreational drug and more importantly, as a potential therapeutic treatment for numerous 
diseases such as wasting syndrome, obesity, and multiple sclerosis (ElSohly 2010).  
B. Cannabinoids 
Isoprene (5 carbon chain) is the basic building block of all terpenoids. A terpenoid is 
defined as two or more isoprene units linked together. These terpenoids can then be linked 
together through biosynthesis to form longer chains or cyclize to form rings. Cannabinoids are a 
chemical class of C21 terpenophenolic compounds that represent a group of compounds found in 
Cannabis sativa. Isolates from Cannabis possessing the C21 terpenophenolic system are known as 
cannabinoids (ElSohly, 2010). The cannabinoids include phytocannabinoids and 
endocannabinoids. Phytocannabinoids are the naturally occurring cannabinoids found in any 
Cannabis species (Pate, 1999). Endocannabinoids are compounds found endogenously that 
activate the cannabinoid receptors.  
It is known that at least 100 cannabinoids have been derived from Cannabis sativa (El-
Alfy et al., 2010). The first cannabinoid identified was cannabigerol, and its precursor, 
cannabigerolic acid, was shown to be the cannabinoid formed in the plant as well as 
endogenously. Likewise, all phytocannabinoids are derived from their respective carboxylic 
acids by methods of decarboxylation. The decarboxylation can occur via heat, light, or basic 
conditions (Yamauchi, 1975). Today, the most discussed phytocannabinoid is 1. Δ9-THC and 
cannabidiol are the two most commonly studied naturally occurring cannabinoids.  
a. Classical Cannabinoids 
i. Major Phytocannabinoids 
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The first class of major cannabinoids is cannabigerol (CBG, 3). It is a non-psychoactive 
constituent found in Cannabis, and is found in higher concentrations in hemp than in the drug 
type Cannabis plants. It is known that cannabigerol displays antibiotic, antifungal, anti-
inflammatory, and analgesic effects. Structurally, the remainder of isolates from this class have 
propyl side chain analogues and a monomethyl ether derivative (ElSohly 2010).  
 
Figure 1.2. The chemical structures of cannabigerol. 
The second class of cannabinoids is the cannabichromenes (CBC, 4). Pharmacologically, 
cannabichromene has been evaluated as a strong anti-inflammatory, an antibacterial, a moderate 
antifungal, and as a slight analgesic (Turner 1981). Recent literature validates that 4 does elicit 
effects in the tetrad assay, meaning it causes psychoactivity. However, administration of a CB1 
antagonist did not reverse the effects of 4, which suggests the endocannabinoid system is much 
more complex than currently understood (DeLong, Wolf et al. 2010). There are presently five 
analogs of 4 with structural differences primarily in the C-5 position (ElSohly 2010).  
OH
HO
COOH
OH
H3CO
COOH
OH
H3CO
OH
HO
COOH
OH
HO
Cannabigerolic acid
Cannabigerolic acid monomethylether
Cannabigerol monomethylether
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Figure 1.3. The chemical structures of cannabichromene.  
After 1, cannabidiol (CBD, 2) is the second most discussed cannabinoid. It accounts for 
approximately 40% of the extracts of fiber type Cannabis (Grlic 1976), and was first isolated in 
1940 (Adams 1940). However, the correct structure was not elucidated until 1963 by Mechoulam 
and Shvo (Mechoulam and Shvo 1963). Cannabidiol is a non-psychoactive component of 
Cannabis said to be responsible for anti-inflammatory, antioxidant, antipsychotic, analgesic, and 
neuroprotective effects. Recently, it has been discovered that 2 also inhibits cancer cell growth 
(Mechoulam, Peters et al. 2007).   
Clinical evidence shows that 2 alone has the ability to dramatically reduce anxiety 
(Bornheim 1995). There is also evidence that 1 and 2 work synergistically to provide positive 
therapeutic effects. For instance, when 1 is taken alone the results show unpleasant side effects. 
However, when 1 and 2 are taken together the unpleasant side effects associated with solo 
administration of 1 are lacking. The reason for this phenomena is that 2 inhibits cytochrome 
P450 3A11, which metabolizes 1 into its more potent derivative, 11-hydroxy-THC (Mechoulam 
2002).  
Structurally, the analogs of 2 vary from C1 to C5 side chains for a total of seven isolated 
phytocannabinoids (ElSohly 2010).  
O
OH
COOH
O
OH
O
OH
COOH
O
OH
Cannabichromenic acidCannabichromene, 4
Cannabichromevarinic acid Cannabichromevarin
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Figure 1.4. The chemical structures of cannabidiol. 
Although isolated in 1942, it took Gaoni and Mechoulam until 1964 to elucidate the 
chemical structure of 1 from the leaves of Cannabis sativa (Gaoni and Mechoulam 1964). Δ9-
tetrahydrocannabinol is pharmacologically and toxicologically the best studied constituent of 
Cannabis, responsible for most of the psychoactive effects of natural Cannabis preparations 
(Grotenhermen 2002). Other than 1 being abused to achieve euphoria, it is now being used 
medicinally to treat patients with acquired immunodeficiency syndrome (AIDS) suffering from 
wasting syndrome as an appetite stimulant. It is also being used for pain management and nausea 
and vomiting associated with patients receiving cancer chemotherapy.  
The pharmacological effects associated with 1 are thought to occur through its interaction 
with the human cannabinoid receptor 1 (CB1). Acting as a partial agonist at CB1, Δ9-THC has 
demonstrated various pharmacological effects such as euphoria, analgesia, appetite stimulantion, 
Cannabidiol, 2 Cannabidiolic acid Cannabidiol monomethylether
Cannabidiol-C4 Cannabidivarinic acidCannabidivarin
Cannabidiorcol
HO
OH
HO
OH
H3CO
OH
HO
OH
HO
OH
HO
OH
COOH
COOH
HO
OH
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reduction of nausea, reduction of intraocular pressure, reduction of neuropathic pain and 
spasticity, anti-inflammatory, antioxidant, and antiemetic (Maurer, Henn et al. 1990). Along with 
all of these potential medicinal uses, recent literature shows promise that 1 may also be used for 
the treatment of Tourette’s syndrome and Alzheimer’s Disease (Ramirez 2005).  
The dibenzopyran moiety is the base structure for all 1 derivatives. Furthermore, the 
location of the double bond at the C-9,10 position is critical for activity at the cannabinoid 
receptors. Current reports show there are nine different Δ9-THC type cannabinoids that have 
been isolated from Cannabis.  
 
Figure 1.5. The chemical structures of Δ9-THC. 
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Similar to 1, Δ8-tetrahydrocannabinol (Δ8-THC, 5) acts as a partial agonist at CB1 and 
also produces psychoactive effects. Though the C-8,9 double-bond position in 5 is 
thermodynamically more stable than the C-9,10 double-bond position in Δ9-THC, 5 is 
approximately 20% less active at the cannabinoid receptors than 1. In turn, this leads to similar 
pharmacological effects that are associated with 1, but much less potent.  
 
Figure 1.6. The chemical structures of Δ8-THC. 
Instead of the typical 6-membered (cyclohexane) A ring, the cannabicyclol (CBL, 6) 
class contains a 5-membered (cyclopentane) ring and C-1 bridge. Cannabicyclol is a non-
psychoactive component of Cannabis, and is formed via heat-degradation from cannabichromene 
(Crombie 1968).  
 
Figure 1.7. The chemical structures of cannabicyclol.  
 The seventh class of major cannabinoids is the cannabielsoin (CBE, 7) type, derived via 
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photochemical oxidation of cannabidiol (Kuppers, Lousberg et al. 1973).Cannabielsoin was 
identified in 1991 using the guinea pig in vitro and in vivo animal model (Gohda 1990).  
 
Figure 1.8. The chemical structures of cannabielsoin.  
Cannabinol (CBN, 8) was the first cannabinoid isolated from Cannabis sativa (Wood, 
Spivey et al. 1896); its structure was then elucidated in 1940 (Adams, Baker et al. 1940). The 
cannabinol class is very similar to 1 and 5 type classes. However, the difference is the 
aromatization of the A ring. This class is derived from oxidative metabolites of 1. Cannabinol 
does show similar pharmacological effects to 1 such as psychoactivity, sedation, antibiotic, 
anticonvulsant, and anti-inflammatory. Due to cannabinol having slightly weaker agonist activity 
for the cannabinoid receptors than 1, the pharmacological effects are rather faint.   
Cannabielsoic acid A Cannabielsoic acid BCannabielsoin, 7
HO
O
H3C OH
HO
O
H3C OH
HO
O
H3C OH
COOH
COOH
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Figure 1.9. The chemical structures of cannabinol. 
 Cannabitriol (CBT, 9) type is a class characterized by an additional hydroxyl (OH) 
substitution resulting in a total of three hydroxyl functional groups. Cannabitriol exists naturally 
in the form of both isomers and the racemate (ElSohly 1977). 
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Figure 1.10. The chemical structures of cannabitriol.  
ii. Minor / Miscellaneous Phytocannabinoids 
 
Figure 1.11. Miscellaneous phytocannabinoids. 
iii. Classical Synthetic Cannabinoids 
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There have been many cannabinoid derivatives synthesized from the base dibenzopyran 
structure of compound 1. With this said, the focus in this section is to discuss some of the most 
potent dibenzopyran derivatives. Some of these derivatives may not equally bind to both 
cannabinoid receptors, but selectively bind to CB1 or CB2. This selectivity may be the 
benchmark for many new therapeutic drugs, which in turn lack the unwanted side effects 
associated with Cannabis use.  
The use of marijuana is illegal in most portions of the world whether it is medicinal or 
recreational. The compounds within marijuana have been intensely studied over the past few 
years, and concluded that 1 is the main psychoactive component. Along with negative effects, 
such as psychoactivity, there are many beneficial effects stemming from 1 activating the 
endocannabinoid system. Thus, synthetic production of 1 and other analogues are currently used 
as treatments for wasting syndrome in AIDS patients and for chemotherapy-induced nausea and 
vomiting.  
Two Food and Drug Administration (FDA) compounds have been approved to aid with 
negative side effects of cancer chemotherapy and AIDS, Marinol® (Dronabinol) and Cesamet® 
(Nabilone). Dronabinol is a molecularly identical version of 1, but it is produced by total 
synthesis rather than isolated from Cannabis. Nabilone has the dibenzopyran base structure of 1, 
but has minor modifications at C-3 and C-9. Both of these drugs are used for anorexia and 
weight loss associated with AIDS and chemotherapy-induced nausea and vomiting (Beal 1995) 
(Ware 2008). Although not marketed for these uses, Nabilone is also beneficial for chronic pain 
management associated with fibromyalgia and multiple sclerosis (Skrabek 2008). Even with all 
the beneficial effects currently associated with these drugs, psychoactivity still prevails.  
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Figure 1.12. Chemical structures of Dronabinol (left) and Nabilone (right). 
Efforts have focused on the synthesis and modifications that mimic the therapeutic 
actions of 1 and the other beneficial phytocannabinoids without the unwanted side effects. At 
Hebrew University, Mechoulam et al. have synthesized numerous tetrahydrocannabinol 
analogues; one in particular is HU-210 (Mechoulam, Lander et al. 1990). This compound 
consists of the base structure of Δ8-THC with a hydroxy substitution at C-11 and a 1,1-
dimethylheptyl chain at C-3. HU-210 shows potency of 100-800 times stronger than that of 1 
(Devane, Breuer et al. 1992).  
 
Figure 1.13. Chemical structure of HU-210. 
A recent research literature report shows that mammals, including humans, are able to 
generate new neurons in the hippocampus. This discovery has changed the way scientists view 
psychiatric disorders and drug addiction (Mandyam 2004). A study performed in 2005 suggests 
that CB1 receptor activation by cannabinoids may promote hippocampal neurogenesis. The goal 
of the study was to determine if HU-210 is to able to promote neuronal generation, which leads 
to the anxiolytic and antidepressant effects associated with the cannabinoids. HU-210 was 
O
OH
Dronabinol
O
O
OH
Nabilone
O
OH
OH
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administered chronically to rats over a one month time period. After one month, the rats 
displayed an increased number of newborn neurons in the hippocampal dentate gyrus. Also, the 
rats showed significantly reduced anxiety- and depression-like behaviors. Therefore, chronic 
administration of HU-210, which fully activates both cannabinoid receptors, does indeed 
promote neuronal growth (Jiang 2005). 
Dexanabinol (HU-211) is the enantiomer of the previously discussed potent cannabinoid 
agonist HU-210 (Pop 2000). Unlike HU-210, it does not activate the cannabinoid receptors and 
therefore does not show psychoactivity (Mechoulam, Feigenbaum et al. 1988). However, it does 
function as an N-methyl-D-aspartate (NMDA) antagonist. The NMDA receptor is a glutamate 
receptor, which involves brain functions such as cognition, memory, movement, and sensation 
(Laube 1997).  
 
Figure 1.14. Chemical structure of HU-211, or Dexanabinol. 
After evaluating HU-211 for cannabinoid-like effects, proof that it acts as an NMDA 
receptor antagonist was needed. A study done in 1989 confirmed that HU-211 blocked 
tremorogenic, convulsive, and lethal effects of NMDA (Feigenbaum 1989). With these 
observations, more thorough pharmacological assays were performed. These tests led to the 
discovery that HU-211 also blocks tumor necrosis factor (TNFα). TNFα is involved in septic 
shock, multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, and cachexia. To 
determine its therapeutic potential, HU-211 was administered in vivo to rats with closed head 
O
OH
OH
HU-211, Dexanabinol
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injury, or brain damage. Treatment with HU-211 showed that TNFα levels were reduced by over 
80%. Thus, HU-211 is a novel drug candidate for neuroprotectant diseases (Shohami 2000).  
Unlike the previously discussed synthetic cannabinoids, the compound JWH-051 shows 
selectivity for the human CB2 receptor. The structural difference from HU-210 is the removal of 
the phenolic hydroxyl group. With activity in the low nanomolar range at CB2, 14nM, JWH-051 
showed promising effects for the cannabinoid receptors and the cytokine network (Huffman 
1996). Though it still retains slight activity for CB1, it is a very potent anti-inflammatory agent.  
The scientific literature provides evidence that when mice infected with Legionella 
pneumophila were administered JWH-051, the production of interleukin-4 (IL-4) increased 
within the spleen. When this cytokine is stimulated, IL-4 causes a cascade of events to occur and 
in turn increases production of T helper cells. Therefore, this process plays a critical role in 
chronic inflammation and wound repair via stimulation of only CB2 receptors (Klein 1998).  
 
Figure 1.15. Chemical structure of JWH-051. 
The link between the cannabinoid system, cannabinoids, and cancerous tumor growth is 
unclear in in vivo animal models. What is known, however, is that administration of 
cannabinoids inhibits tumor growth. Tumor growth progresses due to the generation of a new 
vascular supply, or angiogenesis. Using a synthetic, potent, selective CB2 agonist, JWH-133, 
two mechanisms for inhibition of tumor growth in vivo were proposed in 2003.  
O
OH
JWH-051
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Figure 1.16. Chemical structure of JWH-133. 
To begin the study, malignant tumors were induced in immune-deficient mice. Next, CB2 
selective agonist JWH-133 was administered for eight days at a dose of 50 µg/day. The results 
indicate that the tumors of the cannabinoid-treated mice were smaller than those of the control 
group. To help defend one of the proposed mechanisms of action, differences in vascular 
functionality were assessed. Upon further evaluation, the vascular network of the JWH-133-
treated tumors were small, differentiated, and impermeable, as opposed to normal tumor growth 
that has a large, plastic, and leaky vascular network.  
The next test was to determine whether JWH-133 inhibited tumors from secreting 
proangiogenic cytokines, which in turn leads to formation of a large vascular network. As a 
result, JWH-133 reduced expression of vascular endothelial growth factor. Vascular endothelial 
growth factor is a major contributor to tumor growth by mediating the prevention of vessel 
maturation. Thus, the second proposed mechanism provides proof that JWH-133 does suppress 
proangiogenic factors within the tumor. Overall, this research displays that a CB2 selective 
agonist such as JWH-133 has potential to become a therapeutic treatment for cancer (Blazquez 
2003).  
b. Non-classical Cannabinoids 
The term non-classical cannabinoid refers to any compounds that stimulate the 
cannabinoid receptors that are not structurally related to Δ9-THC. The origin of non-classical 
O
JWH-133
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cannabinoids can be from natural products, endogenous, or created synthetically. There are some 
compounds closely related to the classical cannabinoids, such as CP-55940 and HU-308, and 
there are those that have structures completely different than the classical cannabinoids, such as 
WIN55212-2 and SR141716. Some of the most common classifications of non-classical 
cannabinoids are the aminoalkylindoles, diarylpyrazoles, eicosanoids, and flavonoids.  
i. Non-classical Synthetic Cannabinoids 
Researchers at Pfizer have synthesized new analogues of 1 that lack the dihydropyran 
ring (Melvin 1984). Out of the numerous compounds synthesized, one in particular still remains 
as the most commonly used: CP-55940 (10). CP-55940 is a bicyclic analogue of 1, and is much 
less lipophilic than 1. Since 10 has binding affinity and functional activity much stronger than 
that of 1, it has been developed as a radiolabelled ligand. The development of 3[H]-CP-55940 
was fundamental in the discovery and characterization of the human CB1 receptor (Devane 
1988).  
CP-55940 has the ability to bind to CB1 and CB2 with Ki values of 0.5 nM and 0.7 nM, 
respectively. Furthermore, it showed pharmacological effects in vivo in the tetrad mouse model 
to range from 10 to 50 times stronger than that of 1 (Johnson 1986). CP-55940 is used in 
receptor assays as a control since its maximal effects exceed other cannabinoid agonists; it 
displays similar affinities at CB1 and CB2 and has been deemed a full agonist for both receptor 
subtypes (Pertwee 1999). 
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Figure 1.17. Chemical structure of CP-55940. 
Although not marketed, there is a newly synthesized CB2 receptor selective ligand, HU-
308. It has a selectivity of 5000x for CB2 over CB1. The success in finding a selective ligand for 
the CB2 receptor is the ability to devoid psychoactivity and drug abuse via stimulation of the 
CB1 receptor. A recent study evaluates the potency and pharmacology of HU-308 in an in vivo 
model of liver ischemia reperfusion and in human liver sinusoidal endothelial cells (HLSECs). 
HU-308 was injected into the femoral vein right before the reocclusion in a 10mg/kg dose. To 
determine the amount of tissue damage to the liver, serum transaminase alanine aminotransferase 
and lactate dehydrogenase activities were measured. As hypothesized, pretreatment with HU-308 
significantly reduced the transaminase ALT and LDH levels, proving to be successful (Rajesh 
2007). Furthermore, HU-308 has shown to promote proliferation of neuronal stem cells and 
inhibit TNFα (Rajesh 2007). 
 
 
Figure 1.18. Chemical structure of HU-308. 
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Most discussions about the cannabinoid receptors provide evidence that ligands at these 
receptors have the potential to play a critical role in drug therapeutics, whether acting as agonists 
or antagonists. The existence of cannabinoid receptor antagonists on the market became 
available in 2006 in the United Kingdom (UK) when Rimonabant (SR141716, 11) was 
trademarked as the first selective CB1 inverse agonist. Rimonabant is a member of the 
diarylpyrazole class and was primarily used to reduce appetite for the treatment of obesity, and 
for those who were overweight that had a high risk of type 2 diabetes (Fong and Heymsfield 
2009).  
Even though 11 showed major success in weight loss treatment, it was removed from the 
UK market. In 2009, the European Medicines Agency gave reason of removal due to high rates 
of deleterious side effects associated with psychiatric disorders, such as depression and suicidal 
thought; these adverse events outweighed the benefits of the drug. Although the relationship of 
CB1 receptors and psychiatric effects is not fully understood, it is known that the interaction of 
11 and the CB1 receptors in the brain led to these negative side effects (Katoch-Rouse 2003).  
 
Figure 1.19. Chemical structures of selective CB1 inverse agonists. Rimonabant (left) and AM-
251 (right). 
Another member of the diarylpyrazole class is AM-251, which also acts as a selective 
CB1 inverse agonist. It is structurally very similar to Rimonabant, in which only a chlorine atom 
is replaced with an iodine atom. This substitution causes AM-251 to have almost a two-fold 
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increase in binding potency for the CB1 receptor, 7.5nM for AM-251 and 11.5nM for 
Rimonabant (Katoch-Rouse 2003).  
The structure similarity to 1 for developing cannabinoids was not the case when WIN-
55212-2 was developed. It is a member of the aminoalkylindole class, yet it acts as a cannabinoid 
receptor agonist and produces pharmacological effects similar to those of 1 (Wiley 1998). The 
scientific literature shows that it acts as an analgesic in rat models for neuropathic pain 
(Herzberg 1997). Furthermore, WIN-55212-2’s ability to inhibit adenylate cyclase also allows it 
to reduce intraocular pressure (Pacheco 1991).  
 
 
Figure 1.20. Chemical structure of WIN-55212-2. 
ii. Non-classical Eicosanoids 
The eicosanoids are a class of endogenous, twenty-carbon essential fatty acids that 
stimulate the cannabinoid receptors. In 1992, anandamide was the first described endogenous 
cannabinoid neurotransmitter (Devane 1992). To date, there are five endogenous cannabinoid 
receptor agonists. Of the five discovered, anandamide and 2-arachidonoylglyercol are the two 
most evaluated endocannabinoids in the literature.  
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Figure 1.21. Chemical structure of anandamide. 
c. Noncannabinoid Constituents 
The unique scent of Cannabis results from a group of compounds within the from 
Cannabis known as terpenoids (Turner 1980). There have been approximately 140 terpenoids 
isolated from Cannabis, and the two major monoterpenes identified are myrcene (67%) and 
limonene (17%). Other noncannabinoid constituents include hydrocarbons, nitrogen-containing 
compounds, carbohydrates, fatty acids, phenols, simple alcohols, aldehydes, ketones, acids, 
esters, lactones, vitamin K, and flavonoids (ElSohly 2010).  
Terpenoids and flavonoids have distinct therapeutic effects that include, but are not 
limited to increasing cerebral blood flow, enhancing cortical activity, and eliciting anti-
inflammatory activity (Di Carlo 1999). There are currently twenty-three flavonoids that have 
been identified in Cannabis, with cannflavins A and B (Figure 1.31) being unique to Cannabis 
(Barrett 1986). Humans consume flavonoids each day from fruits and vegetables in their daily 
diet. A review article published in 1999 states that flavonoids may be responsible for inhibition 
of specific enzymes, antiulcer, antispasmodic, anti-secretory, anti-inflammatory, anti-cancer, 
analgesic, anti-angina, anti-diabetic, anti-allergic, and vascular protection. Once flavonoids are 
absorbed, they influence many biological functions making them a target for a variety of diseases 
(Di Carlo 1999).  
N
H
O
OH
Anandamide
 
 21 
 
 
Figure 1.22. Chemical structures of isolated flavonoids from Cannabis sativa. Cannflavin A 
(left) and cannflavin B (right). 
 The use of flavonoids as anti-inflammatory agents has a long standing history (Harborne 
1967), principally by inhibiting production of prostaglandins and leukotrienes (Landolfi 1984). 
Not only do flavonoids show anti-inflammatory activity, but also show anti-ulcerogenic activity. 
The mechanism in by which flavonoids exert anti-ulcerogenic properties is currently unknown. 
Therefore, flavonoids can be therapeutically beneficial in many ways, but their mechanism of 
action for some of the effects still need to be characterized (Villar 1984).  
C. G Protein-Coupled Receptors  
Cannabinoid receptors are G protein-coupled receptors, which are a large family of seven 
membered transmembrane domains that act in a second messenger fashion (Galiegue 1995). 
These receptors couple primarily to the Gi/Go subtypes of G protein. When cannabinoid 
receptors are activated, they inhibit the enzyme adenylate cyclase. Adenylate cyclase is 
responsible for catalyzing the conversion of adenosine triphosphate (ATP) to form cyclic AMP 
(cAMP). When a ligand binds to the extracellular surface of cannabinoid receptors, it causes a 
conformational change of the receptor. This change activates the second messenger by 
exchanging guanosine diphosphate (GDP) for guanosine triphosphate (GTP). Then, the G-
protein’s α subunit separates from the βγ subunit to cause intracellular proteins to function 
properly. In CB1 and CB2 receptors, cAMP acts as the second messenger. When these receptors 
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are activated, cAMP levels decrease within the cell. Therefore, the result of activating 
cannabinoid receptors leads to a decrease in cAMP levels, and in turn leads to an inhibition of 
function (Hwangopo 2005). 
 
Figure 1.23. Example of a G Protein-Coupled Receptor. 
 There are currently two reported subtypes of human cannabinoid receptors, cannabinoid 
receptor 1 (CB1) and cannabinoid receptor 2 (CB2) (Gerard 1990). CB1 and CB2 share 
approximately 44% similarity in their protein sequences (Munro, Thomas et al. 1993). However, 
if only nucleotide sequences are considered, they share approximately 68% similarity (Galiegue 
1995). Recently, there has been evidence that additional cannabinoid receptors, such as GPR18, 
GPR55, and GPR119, may exist (Begg 2005). Of these three potential cannabinoid receptors, 
GPR55 has the most similarity to CB1 and CB2 at the binding site (Ryberg 2007). The reason 
these receptors are believed to be cannabinoid receptors is due to their activation by known 
endogenous cannabinoids.  
 Reports show that GPR18 is the abnormal cannabidiol receptor. This research suggests 
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that N-arachidonyl glycine activates GPR18 and initiates microglial migration in the brain 
(Gantz 1997). GPR119 is expressed primarily in the gastrointestinal tract and pancreas in 
humans. In rat models, activation of GPR119 was shown to reduce food intake and body weight. 
Therefore, drugs that target this receptor have the potential to treat obesity and diabetes (Izzo 
2010).  
 GPR55 was identified and cloned in 1999. It is expressed in the brain, small intestine, and 
bone (Sawzdargo 1999). Originally, GPR55 was considered the third cannabinoid receptor 
because in silico research showed similarities in the amino acid binding site when compared to 
CB1 and CB2 (Baker, Pryce et al. 2006). Furthermore, recent research shows that GPR55 is 
activated by several endocannabinoids, Δ9-THC, Δ8-THC, and CP-55940 in the low nanomolar 
range. The activation of the receptor by these ligands provides more evidence that GPR55 could 
be considered the third cannabinoid receptor (Ryberg 2007).  
D. Endocannabinoids 
Endogenous cannabinoids, or endocannabinoids, are substances produced in the body that 
are capable of binding to and functionally activating the cannabinoid receptors (Di Marzo 1995). 
Generally, neurotransmitters are stored in intracellular compartments and released 
presynaptically to activate the receptors on a postsynaptic cell. However, unlike most 
neurotransmitters, the endocannabinoids work in a reverse fashion. Endocannabinoids use 
retrograde signaling to achieve cannabinoid receptor activation. This means that the ligands are 
being produced postsynaptically, but acting presynaptically (Hanuš 2009). Another critical point 
in understanding the function of the endocannabinoids is that the endocannabinoid system can 
produce endocannabinoids “on demand” in response to an increase in intracellular calcium levels 
(Di Marzo 1998). 
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Shortly after the cloning of the cannabinoid receptors, researchers began searching for 
endogenous ligands that activated these receptors. As previously stated, the first 
endocannabinoid discovered was anandamide in 1992 (Devane 1992). Several years after the 
discovery of anandamide, the second endogenous ligand, 2-arachadonoyl-glycerol (2-AG), was 
discovered (Mechoulam, Ben-Shabat et al. 1995). Anandamide and 2-AG act as a partial agonist 
and full agonist, respectively, at the CB1 and CB2 receptors. Three other endogenous ligands 
have also been discovered: 2-arachidonyl-glyceryl ether (noladin, 2-AGE), O-arachidonyl-
ethanolamine (virhodamine, OAE), and N-arachidonyl-dopamine (NADA) (Bisogno 2005). 
Although the structure of anandamide differs significantly from 1, both of these ligands have 
similar pharmacological profiles (Grotenhermen 2002).  
 
Figure 1.24. Chemical structure of 2-AG. 
Although the physiological roles of the endocannabinoids are not fully defined, several 
pharmacological functions have been described. Studies suggest that these endogenous ligands 
may aid in pain relief, enhancement of appetite, blood pressure lowering during shock, 
embryonic development, and blocking of working memory (ElSohly 2010).  
E. Cannabinoid Receptor 1 
The CB1 receptor is encoded by the CNR1 gene, and is widely expressed throughout the 
brain. It is also expressed in the spinal cord, pituitary gland, thyroid gland, adrenal gland, fat 
cells, muscle cells, liver cells, digestive tract, lungs, kidneys, and male and female reproductive 
organs. Gerrard et al. cloned the rat cannabinoid receptor (Gerard 1991) and shortly after, 
isolation of a human CB1 receptor cDNA was reported (Matsuda 1990).The amino acid 
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sequence contained 472 total amino acids, one less than other mammalian species (Matsuda 
1990). This receptor has been the target of much research due to the pharmacological effects 
associated with its activation.  
As with all G protein-coupled receptors, CB1 possesses seven transmembrane domains 
connected by three extracellular loops and three intracellular loops, an extracellular N-terminal 
tail, and an intracellular C-terminal tail (Elphick 2001). Activation of the CB1 receptor can be 
endogenously or through administration of exogenous cannabinoids. Since CB1 receptors are 
primarily located in the brain, Δ9-THC is reported to bind to this receptor and is responsible for 
the psychoactivity associated with the cannabinoid receptors (Dewey 1986).  
Since CB1 receptors are not present in the medulla oblongata, part of the brain stem 
responsible for respiratory and cardiovascular functions, there is not a risk of overdose resulting 
in respiratory depression or cardiovascular failure that may be seen with abuse of other drugs, 
such as the opioids (Holland, Schwope et al. 2011). Among many other therapeutic uses, ligands 
acting as agonists at CB1 have the potential to aid with wasting syndrome associated with AIDS, 
nausea and vomiting associated with cancer chemotherapy, and as an analgesic for neuropathic 
pain associated with multiple sclerosis. Conversely, inverse agonists, have the potential to help 
with obesity and type 2 diabetes.  
F. Cannabinoid Receptor 2 
Shortly after characterizing and cloning the human CB1 receptor, the CB2 receptor was 
cloned. The CB2 receptor is encoded by the CNR2 gene (Munro, Thomas et al. 1993). The 
amino acid sequence contains approximately 360 total amino acids. The CB1 and CB2 receptors 
have approximately 44% similarity of their amino acid sequences (Cabral 2009). Using computer 
modeling, ligand-induced receptor selectivity between CB1 and CB2 appears to occur at CB2 
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receptor residues S3.31 and F5.46. It is thought that the lipophilic portion of the ligand binds to 
the F5.46 residue and causes a conformational change, allowing the ligand to form a hydrogen 
bond with the S3.31 residue, and in turn cause the pharmacological effects associated with CB2 
interaction (Tuccinardi 2006).  
These receptors are widely expressed throughout the peripheral tissues of the immune 
system, spleen, tonsils, thymus, and gastrointestinal system (Galiegue 1995). Further 
investigation of CB2 receptors led to the discovery that these receptors are also expressed within 
the brain (Onaivi 2006). However, unlike CB1 receptors that are found on neurons, the CB2 
receptors are found on microglia (Cabral 2008). The CB2 receptors play a major role in 
inflammatory diseases due to their interaction with these receptors in the immune system. 
Furthermore, since the discovery of CB2 receptors in the brain, researchers believe that 
interaction with these receptors cause the antinociceptive effects associated with cannabinoids 
(Ibrahim 2006). This could be the milestone for developing novel therapeutic drugs used for pain 
that do not have addictive properties.  
Along with anti-inflammation and antinociception, current research shows that CB2 
receptors may have a role in the treatment of Alzheimer’s Disease (Benito 2003). Alzheimer’s 
disease forms plaques within the brain that disrupts neuronal function. These plaques are formed 
from aggregation of beta-amyloid proteins (Tiraboschi 2004). A CB2 selective agonist, JWH-
015, has shown to induce macrophages to remove beta-amyloid proteins (Tolon 2009). The 
range of diseases associated with cannabinoid receptors is vast and the use of selective 
agonists/antagonists holds strong potential for use with these diseases.  
G. Medicinal Uses 
According to the United Nations, Cannabis “is the most widely used illicit substance in 
 
 27 
 
the world” (2010). There are people who use Cannabis medicinally, and there are others who 
abuse Cannabis in order get “high,” or obtain a state of euphoria. Those who use marijuana 
regularly for medicinal purposes use strict, smaller amounts to control the strength and duration 
of the psychoactivity. However, those who abuse marijuana attempt to smoke or ingest as much 
as necessary to achieve their own personal state of euphoria. 
This abuse negatively affects the people who need Cannabis to help with unwanted side 
effects associated with cancer chemotherapy and AIDS. Cannabis is not only used to help those 
suffering from cancer chemotherapy and AIDS, but it also lowers intraocular pressure for those 
with glaucoma, acts as a pain reliever, and more recently has been found to help with symptoms 
of multiple sclerosis and depression. Therefore, researchers are attempting to formulate synthetic 
cannabinoids that resembles the compounds isolated from Cannabis, but do not express 
psychotropic properties. 
a. Appetite 
Patients suffering from AIDS, cancer chemotherapy, and obesity are now becoming the 
main target for the therapeutic use of Cannabis, or synthetic cannabinoids. The literature 
provides evidence that the use of marijuana does increase appetite via agonism at CB1, which 
can increase energy in daily life routines. Contrary to some of the therapeutic effects via agonists 
at CB1, an inverse agonist has the potential to treat obesity, which in turn can treat type 2 
diabetes. Whether it is a natural or synthetic preparation, the use of cannabinoids has a major 
effect on appetite (Berry and Mechoulam 2002).   
i. Stimulant – Wasting Syndrome 
Elderly patients whose kidneys fail to retain sodium (Harrigan 2001) and patients with 
AIDS tend to lose their desire to eat regularly throughout the day. When this occurs, the patient 
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becomes weak, agitated, tired, and anorexic; this occurrence is known as Wasting Syndrome. 
Research shows that at least 90% of patients who smoke marijuana had an immediate desire to 
eat (Haines 1970). With the use of Cannabis as a therapeutic drug to stimulate appetite, the 
suffering patients may be able to eat on a regular basis throughout the day, thus improving their 
quality of life.  
In a study conducted by Mattes and colleagues, the appetite stimulating effects of 
cannabinoids, specifically Δ9-THC, were examined. A major focus in this study, for a means of 
clarification from previous research, was the route of administration of 1. The four different 
ways in which 1 was administered includes oral, inhaled, sublingual, and suppository. There are 
high levels of variability in determining if 1 does indeed stimulate appetite. Factors such as 
environment, age, gender, tolerance, dosage, and social influences play a role in the effect of 1 
on appetite. During one study, the suppository route of administration resulted in the highest 
energy intake when compared to oral, sublingual, and inhaled administration of 1.  
 
Figure 1.25. Mean data from patients dosed orally and via suppository over a 72 hour time 
period (Mattes, Engelman et al. 1994). License Number: 2850411374927  
 
There is no single outcome on the effect of Δ9-THC on appetite stimulation no matter the 
form of administration. The results vary from having no effect to the possiblity of having major 
food cravings. In some circumstances, not only did the food cravings become increased, but 
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during a meal the food seemed to also have an increased taste of delightfulness. The conclusion 
of this study indicates that 1 as an appetite stimulant produces its highest effects on healthy, adult 
individuals who use low dosage amounts (Mattes, Engelman et al. 1994). 
ii. Suppressant – Obesity 
Obesity is a medical condition in which excess body fat accumulates in a person and 
increases the chances of developing other, more serious conditions such as heart disease and type 
2 diabetes (Jarvis 2006). Currently, there is only one drug approved by the FDA for the treatment 
of obesity, Xenical. This drug helps weight loss by inhibiting pancreatic lipase (1999). In 
Europe, Rimonabant was once used as a treatment for obesity. It stayed on the market for three 
years and was later removed due to psychological side effects. Rimonabant acts an inverse 
agonist at the CB1 receptor (Fong and Heymsfield 2009). Contrary to the appetite stimulating 
effects of Δ9-THC, Rimonabant displays appetite-suppressing effects.  
New drugs targeting the CB1 receptors for the treatment of obesity are currently being 
investigated. The objective of these potential therapeutic compounds is to stimulate CB1 
receptors acting as inverse agonists, but to not cross the blood-brain-barrier and act via the CNS. 
Thus, compounds should interact with CB1 receptors in peripheral organs and avoid the 
interaction with CB1 receptors in the CNS. This means that peripheral CB1 receptors may be the 
key to unlocking the treatment of obesity, type 2 diabetes, and dyslipidemia without having the 
psychological side effects seen with Rimonabant (Nogueiras 2008).  
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Figure 1.26. Proposed mechanism of action of CB1 receptor inverse agonists for the treatment of 
obesity. 
b. Nausea and Vomiting 
Cancer chemotherapy is ultimately defined as the treatment of cancer using an 
antineoplastic drug. The objective of chemotherapy is to kill the rapidly dividing cancerous cells; 
however, rapidly dividing healthy cells are also harmed (Skeel 2003). Along with many others, it 
has been reported that nausea and vomiting are the two most feared side effects of cancer 
chemotherapy. This fear of nausea and vomiting can be so overwhelming that a patient decides 
to not partake in chemotherapy (Coates, Abraham et al. 1983). Though many patients use these 
synthetic drugs, a handful of doctors and patients still choose Cannabis as a preferred treatment.  
Contrary to popular belief, cannabinoids are not easily prescribed, but only used when 
patients are unresponsive to other antiemetic agents. Beside the use of the natural Cannabis plant, 
the synthetic cannabinoids most commonly used are Dronabinol, Nabilone, and Nabiximols 
(Sativex). Dronabinol is a synthetic replica of 1, Nabilone is a synthetic cannabinoid with minor 
structure changes of 1, and Nabiximols is a combination of 1 and 2 formulated into a buccal 
spray. All of these treatments interact with both CB1 and CB2 receptors. The interaction of these 
compounds with CB1 causes the psychoactive effects associated with Cannabis use (Pertwee 
2005). The ultimate goal for cannabinoids and antiemetic drug therapy associated with 
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chemotherapy-induced nausea and vomiting is to develop compounds that display the beneficial 
pharmacological effects without the unwanted side effects, such as psychoactivity.  
c. Depression 
Depression may be described as a mood disorder that interferes with every day life, and is 
associated with feeling down, sad, angry, or lost. The most commonly associated drug categories 
for the treatment of depression include monoamine oxidase inhibitors (MAOIs), tricyclic 
antidepressants (TCAs), selective-serotonin reuptake inhibitors (SSRIs), and serotonin-
norepinephrine reuptake inhibitors (SNRIs). A new field of research involving Cannabis may 
include a potential link to the treatment of depression. However, studies show conflicting data as 
to whether Cannabis is beneficial (Grinspoon 1998) or detrimental for the treatment of 
depression (Bovasso 2001). Due to the conflicting results of these studies, Witkin switched the 
focus to the role of the endocannabinoid system and the treatment of depression from 
exogenously administered cannabinoids (Witkin 2005). Since 2005, it has been concluded that 
the endocannabinoid system does play a role in the treatment of depression, but differs from 
minor depression to major depression. 
New research has found that a common characteristic of Cannabis, mood elevation, may 
be the link to the treatment of depression. A study published by El-Alfy and co-investigators in 
2010 describes the antidepressant effects associated with administration of phytocannabinoids. 
The objective of this study was to isolate the major cannabinoids from Cannabis and evaluate the 
antidepressant effects using the mouse forced swim test (FST), followed by the tail suspension 
test (TST). Typically in mice, when cannabinoids are administered they exert hypothermia and 
catalepsy, which means that a psychoactive state is being achieved. For these depression studies, 
only low dosages of these phytocannabinoids were administered so that the test subjects did not 
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demonstrate psychoactivity.  
To ensure that hypothermia and catalepsy were not achieved, the tetrad assay was 
completed after administration of each cannabinoid. Out of the six cannabinoids tested, only Δ9-
THC and Δ8-THC showed a U-shaped dose response in the forced swim test. With this, only Δ9-
THC showed significant antidepressant-like effects. Administration of the non-psychoactive 
components revealed that cannabidiol and cannabichromene displayed antidepressant-like effects 
in the forced swim test. However, a high dose of cannabidiol was used to display these 
antidepressant-like effects. 
        
          
Figure 1.27. Effects of each phytocannabinoid on immobility time in the mouse forced swim test 
(El-Alfy 2010). License Number: 2850411159444 
To further confirm these tests, Δ9-THC and cannabichromene were evaluated in the tail 
suspension test. Between these two phytocannabinoids, only 1 continued to exhibit these 
antidepressant-like effects at low doses. Therefore, the results of this study show that 1 and other 
phytocannabinoids administered exogenously do indeed aid with the treatment of depression (El-
Alfy 2010). 
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Figure 1.28. Effects of 1 and 4 on immobility time in the mouse tail suspension test (El-Alfy 
2010). License Number: 2850411159444 
d. Multiple Sclerosis 
Multiple sclerosis (MS) is an inflammatory disease in which myelin sheaths surrounding 
the axons in the CNS are impaired. In turn, this leads to demyelination. There is currently little 
treatment for the pharmacological effects associated with MS, such as spasticity, tremors, and 
pain (Compston and Coles 2008). However, studies have shown promising results evaluating 
cannabinoids for the treatment of MS. For instance, results from experiments with animal models 
of MS have shown a major reduction in tremors and spasticity. These positive effects result from 
agonists binding to CB1 and CB2 receptors. Evidence indicates that in animals with 
encephalomyelitis, CB1 and CB2 agonists decrease spasticity, and that CB1 inverse agonists 
increase spasticity (Baker 2000).  
A questionnaire was distributed to patients who were using Cannabis to self medicate 
themselves. The result of this questionnaire showed that over 90% of patients experiencing 
symptoms showed improvement after Cannabis use. Although there is evidence that Cannabis 
and/or cannabinoids are effective against side effects associated with MS, further research needs 
to be done to determine the exact mechanism of action by which these cannabinoids are working 
(Pertwee 2002).  
e. Analgesic 
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The use of opioid analgesics has been around for many years. Although they work very 
well for pain management, they display dangerous side effects such as addiction, tolerance 
development, and respiratory depression leading to death. The role of cannabinoid receptors as a 
therapeutic treatment for neuropathic pain has significantly increased in recent years. Since the 
discovery of CB2 receptors in the CNS, compounds have been synthesized to selectively target 
these receptors (Onaivi 2006). The strong therapeutic potential for cannabinoids as 
antinociceptive medication arises from the development of CB2 selective compounds in order to 
avoid the psychoactivity associated with the CB1 receptor (Munro, Thomas et al. 1993).  
Compounds such as HU-308 have been developed and evaluated as CB2 selective 
agonists. HU-308 exhibits anti-inflammatory and antinociceptive properties through activation of 
the CB2 receptors. As a potential therapeutic candidate, it was necessary to determine if HU-308 
showed CNS activity in the tetrad assay. As a result, lack of CB1 activation did indeed result in 
the absence of CNS psychoactivity. To ensure that CB2 selective agonists are only activating 
CB2, administration of CB1 and CB2 antagonists are administered to determine if the effects are 
reversed. Thus, CB2 selective agonists have the potential to be a non-psychoactive and non-
addictive treatment for pain management (Hanus 1999).  
For the past several years, Cannabis has been the most commonly used drug in the United 
States. The use of Cannabis comes with both benefits and risks to human health. The negative 
side effects associated with Cannabis outweigh the beneficial effects, making it an illegal drug, 
without prescription, in the United States. A few of the negative effects associated with Cannabis 
are euphoria, heart rate changes, and impairment of cognitive function. Some of the main 
beneficial effects are factors that aid with pain, appetite, and inflammation associated with 
numerous diseases. Since there have been no reports associated with death from Cannabis 
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ingestion, the pursuit of Cannabis and cannabinoids as therapeutics may be the future for the 
treatment of many diseases and disorders (ElSohly 2010).  
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CHAPTER II 
ENDOCANNABINOID SYSTEM 
The discovery of the endogenous cannabinoid system, or endocannabinoid system, came 
shortly after the discovery of the cannabinoid receptors. The endocannabinoid system refers to 
the cannabinoid receptors, endogenous cannabinoids, and the proteins for their synthesis and 
inactivation. Endogenous cannabinoids, or endocannabinoids, are compounds produced within 
the body that are capable of functionally activating the cannabinoid receptors (Di Marzo 1995). 
To date, there have been five endocannabinoids discovered (Figure 2.1). Although the 
mechanism of action for all of them is not clear, they appear to have a role in appetite, pain, 
mood, and memory.  
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Figure 2.1. Chemical structures of the endogenous cannabinoids. 
Most neurotransmitters are stored in vesicles until needed. Once activated, they are 
released presynaptically to activate the receptors on a postsynaptic cell. The endocannabinoids, 
however, work oppositely. They use retrograde signaling in order to achieve receptor activation. 
This means they are produced postsynaptically, but are acting presynaptically (Hanuš 2009). 
Endocannabinoids are not stored in vesicles, but are produced “on demand” in response to an 
increase in intracellular calcium levels (Di Marzo 1998).  
N-arachidonyl-ethanolamine (AEA) was the first endogenous ligand discovered in 1992. 
It was later named anandamide from the Sanskrit word ananda, meaning “internal bliss,” and the 
presence of the amide functional group (Devane 1992). It belongs to the family of N-acyl-
ethanolamines (NAEs), and like all endocannabinoids, is derived from arachidonic acid (Bisogno 
2000). Anandamide acts as a partial CB1 agonist and a weak CB2 agonist (Pertwee 1997). In 
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1995, 2-arachidonoylglycerol (2-AG) was described as the second endocannabinoid discovered 
(Mechoulam, Ben-Shabat et al. 1995). It acts as a full agonist at CB1 and CB2 receptors (Sugiura 
1995). A few years later, 2-arachidonyl-glyceryl ether (noladin, 2-AGE) (Hanus 2001), O-
arachidonoyl-ethanolamine (virodhamine, OEA) (Porter 2002), and N-arachidonoyl-dopamine 
(NADA) (Bisogno 2000) were discovered, and all displayed functional activity for the 
cannabinoid receptors. Noladin and NADA are selective CB1 agonists, while virodhamine is a 
CB1 antagonist and partial CB2 agonist (Bisogno 2005). 
A.  Biosynthesis of AEA 
Previously reported studies indicate that AEA is biosynthesized via a phospholipid-
dependent pathway consisting of the enzymatic hydrolysis of N-acyl-phosphatidylethanolamines 
(NAPEs) (Schmid 1983). The enzyme that catalyzes this reaction is phospholipase D selective 
for NAPEs. These phospholipid precursors are produced from the transfer of the acyl group from 
the sn-1 position of phospholipids to the N-position of phosphatidylethanolamine. This 
enzymatic transfer reaction is catalyzed by a Ca2+ dependent trans-acylase. Although other 
mechanisms have been reported, evidence points to this mechanism most likely responsible for 
AEA biosynthesis (Figure 2.2) (Ueda 2001). 
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Figure 2.2. Biosynthesis of AEA. NaPE: N-arachidonoylphosphatidylethanolamine, PLD: 
phospholipase D. 
B.  Biosynthesis of 2-AG 
The biosynthesis of 2-AG results from the hydrolysis of diacylglycerols (DAGs) 
containing arachidonate in the 2 position (Figure 2.3) (Bisogno 1997). DAGs can be produced 
from hydrolysis of phospholipase C, phosphoinositides, or phosphatidic acid. The conversion of 
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DAGs to 2-AG is catalyzed by a DAG lipase selective for the sn-1 position (Bisogno 1999). 
Currently, there are two DAG lipases that have been cloned, DAGLα and DAGLβ, and are said 
to be responsible for the formation of 2-AG (Bisogno 2003). Functionally, there is a number of 
suggestions portraying 2-AG’s function as a mediator of neuronal growth (Bisogno 2003) 
(Williams 2003) (Chevaleyre 2003).  
 
Figure 2.3. Pathways for the biosynthesis of endocannabinoid, 2-AG. 
In regard to noladin, virodhamine, and NADA, very little is known about their physiological 
roles. 
C.  Inactivation of Endocannabinoids 
Similar to other endogenous ligands, it is critical to have a rapid and selective mechanism 
of inactivation. Endocannabinoids are highly lipophilic compounds, which allows for them to 
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diffuse easily through the cell membrane. However, removal of endocannabinoids through the 
plasma membrane requires methods such as facilitated transport. There are several proposed 
mechanisms for how anandamide is taken up by cells, but the most common mechanism is 
known as the anandamide membrane transporter (AMT) (Di Marzo 1994).  
The AMT has not been isolated or cloned, but reports indicate that it may also be 
responsible for the uptake of all five endocannabinoids (Huang 2002). The process of 
endogenous inactivation is sensitive to factors such as saturation, temperature, and synthetic 
inhibitors (Beltramo 1997). Contrary to the proposed mechanism of the AMT, recent reports 
suggest that fatty acid amide hydrolase (FAAH) is the enzyme responsible for hydrolysis of 
anandamide to its inactive state. The scientific literature shows that FAAH does influence 
anandamide uptake, but other mechanisms of action are also necessary to enhance the rate at 
which endocannabinoids are metabolized (Cravatt 2003).  
In 2004, a study was conducted using a synthetic compound, UCM707, which inhibits 
AEA uptake inactive against FAAH.  The author’s results suggest that both CB1 receptors and 
FAAH play a role in the cellular uptake of AEA. There was also evidence suggesting that an 
additional protein inhibited by UCM707 also participated in AEA uptake (Ortega-Gutierrez 
2004).  
 
 
Figure 2.4. Chemical structure of a synthetic inhibitor of FAAH. 
Anandamide and 2-AG each have their own pathways of degradation once inside the cell. 
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However, one similar mechanism of inactivation is through hydrolysis catalyzed by FAAH. For 
AEA and 2-AG, degradation via FAAH results in arachidonic acid and ethanolamine or glycerol, 
respectively (Cravatt 1996). The first crystal structure of FAAH was published in 2002 (Bracey 
2002), followed by its ability to breakdown anandamide in 2003 (Deutsch 1993). FAAH’s 
primary function is to catalyze the hydrolysis of long chain fatty acid amides and glycerol esters 
(Patricelli 2000).  
One study reported that in FAAH knockout mice, levels of N-acylethanolamines were 
elevated in various tissues. Due to the lack of hydrolysis by FAAH, anandamide levels were 
significantly increased. Furthermore, reports indicated that the mice displayed extreme 
sensitivity to exogenous administration of cannabinoid agonists. Therefore, the ability of FAAH 
to regulate pain has pioneered an interest for novel antinociceptive therapeutics (Cravatt 2001).  
The scientific literature indicates that FAAH may not be the only enzyme responsible for 
the hydrolysis of 2-AG; monoacylglycerol lipases (MAGLs) may also inactivate this endogenous 
cannabinoid (Ben-Shabat 1998). Currently, a MAGL that is inactive on AEA has been cloned 
from mouse, rat, and human. Interestingly, in rats, this MAGL has been found in the brain and is 
located in areas of CB1 receptor abundance. Immunohistochemical studies in the hippocampus 
confirmed the role of MAGL in the degradation of 2-AG as a retrograde messenger due to the 
presynaptic localization of the enzyme (Dinh 2002).  
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Figure 2.5. Mechanisms for inactivation of 2-AG and anandamide. FAAH: fatty acid amide 
hydrolase, MAGL: monoacylglycerol lipase. 
Esterification and oxidation are also two mechanisms in which endocannabinoids may be 
inactivated. For example, 2-AG can directly become inactivated, i.e. MAGLs, or it can be re-
esterified into phospholipids before hydrolysis. This re-esterification is possible due to 
phosphorylation or acylation of its hydroxyl groups (Sugiura 2002). For all the 
endocannabinoids, oxidative mechanisms may also cause inactivation. The presence of the 
arachidonate moiety allows for high possibilities of oxidation catalyzed by lipoxygenases, 
cyclooxygenases, and cytochrome P450 oxidases (Kozak 2002).  
D.  The Role of Endocannabinoids in Potential Therapeutic Drugs 
The objective in targeting the endocannabinoid system for new therapeutic drugs is to 
enhance endogenous half-life, or preventing their inactivation. One study shows that targeting 
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the endocannabinoids, specifically anandamide, may be responsible for modulation of emotional 
states in rats. Similar to the effects of marketed benzodiazepines for anxiety, synthetic inhibitors 
of FAAH have also displayed promising results in reducing anxiety. To prove these compounds 
were acting via cannabinoid receptors, the CB1 inverse agonist Rimonabant prevented 
inactivation of FAAH. Along with anxiolytic properties, administration of the FAAH inhibitors 
also displayed antinociceptive properties. This reveals a key role of anandamide in the regulation 
of emotional states and potential for novel anti-anxiety therapeutics (Kathuria 2003).  
  There are numerous effects observed in animal models with the therapeutic modulation 
of the endocannabinoid biosynthesis and degradation. Endocannabinoid inhibitors can alleviate 
spasticity associated with multiple sclerosis (Baker 2000), allergic encephalomyelitis (Mascolo 
2002), intestinal hyperactivity caused by cholera toxin (Izzo, Capasso et al. 2003), movement 
associated with Parkinson’s disease and hyperactivity in glutamatergic neurons (Gubellini 2002). 
Furthermore, it is known that the endocannabinoid system is also involved in the pathway that 
leads to drug and alcohol addiction (Tanda 1997). Further clarification of the physiological role 
of anandamide and 2-AG, along with virodhamine, noladin, and NADA, may answer the 
mystery that remains with the endocannabinoid system and their use as potential therapeutic 
drugs.  
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CHAPTER III 
METHODS 
A. Rationale for the Development of the Bioassays 
Most of the current drugs on the market that target G protein-coupled receptors were not 
initially designed to target these specific proteins. Functional activity was the sole determinant as 
to whether potential drugs of interest were pursued. It was not until years later that researchers 
discovered the functional activity seen correlates to a specific receptor. Currently, approximately 
27% of all drugs approved by the FDA target G protein-coupled receptors (Overington 2006). 
Therefore, natural products that have known beneficiary pharmacological effects via the 
endocannabinoid system, which activate G protein-coupled receptors, should be extensively 
pursued in an attempt to discover novel ligands that activate their receptors. Activation of the 
cannabinoid receptors provides positive effects, but may also display several unwanted side 
effects. These negative side effects could be overcome by the development of selective 
compounds for each specific receptor.  
The ability of ligands to activate the cannabinoid receptors and exhibit many beneficial 
therapeutic effects attracts further scientific research. Reports of Cannabis use for certain 
ailments dates back for thousands of years for numerous illnesses and diseases. In these several 
thousand years, there has yet to be a death attributed to solely Cannabis use (Stott 2004). 
Therefore, the pursuit of cannabinoid receptors as novel drug targets is of major interest in 
pharmaceutical industries. These receptors can mediate signal transductions associated with pain, 
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cardiovascular activity, cancer, gastrointestinal activity, obesity, AIDS, appetite, depression, 
anxiety, neurodegenerative disorders, immune function, and drug addiction (Husni 2012). The 
combination of excellent characteristics of Cannabis and the rise of cannabinoid receptor-based 
disorders warrants further investigation to help understand the unknown mechanisms of action 
responsible for binding and stimulation. The use of radiolabeled receptor binding and functional 
bioassays may lead to the discovery of novel therapeutics.  
B. In Vitro Bioassays 
a. Cell Culture 
Human Embryonic Kidney (HEK) 293 cells (ATTC: CRL-1573) are a specific cell line 
commonly used in biological labs due to their ease of growth and transfection. Parental HEK293 
cells were stably transfected via electroporation with full-length human recombinant cDNA for 
cannabinoid receptor subtypes 1 and 2. The human recombinant cDNA was obtained from 
Origene. During electroporation, the cells open by getting “shocked,” which allows them to 
accept the cDNA. Once transfected, the cells are maintained at 37°C and 5% CO2 in a 
Dulbecco’s Modified Eagle’s medium (DMEM) nutrient mixture F-12 HAM supplemented with 
2 mM L-glutamine, 10% fetal bovine serum (FBS), 0.5% penicillin-streptomycin, and G418 
(Geneticin, 600 mg/mL). The use of G418 as an antibiotic allows for only those cells that have 
received the cDNA to survive during the growth and maturation process. This is due to the 
genetic resistance of this antibiotic being incorporated into the cDNA, which includes the gene 
for CB1 or CB2. Those cells that survive will attach to the bottom of the cell culture plate and 
begin replicating. 
A single cell is picked from the parental plate and forced to replicate on its own in a fresh 
plate with the appropriate media. The use of a single cell guarantees the overexpression of the 
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receptors on the cell membrane for each receptor subtype, CB1 and CB2. After the single cell 
multiplies, it is termed a single colony. This colony was at least 90% confluent before it is 
passaged into larger preparations for mass cell culture. Membranes are prepared by scraping the 
cells in a 50 mM Tris-HCl buffer, homogenized via sonication, and centrifuged for 40 minutes at 
13,650 rpm at 4°C. These cells are stored at -80°C until used for the binding and functional 
assays. For clarification, the development of individual CB1 and CB2 cell lines was achieved. 
Protein concentration for each membrane preparation was found using the Bradford protein assay 
protocol reported in 1976 (Bradford 1976). 
  
Figure 3.1. Single cell (left) replicated into a single colony (right). 
To ensure the correct cDNA sequence and protein was transfected within each cell line, 
polymerase chain reaction (PCR) and Western blot assays are performed. PCR has the ability to 
amplify DNA across many orders of magnitude, which allows for generation of DNA sequencing 
(Saiki 1988), and the Western blot assay uses gel-electrophoresis to detect the specific proteins 
within a cell culture preparation (Towbin 1979).  
b. Radioligand Competitive Binding Assay   
Synthetic, endogenous, or natural cannabinoids may be tested for their binding affinity 
toward each of the cannabinoid receptors. Any of these compounds tested are hypothesized to 
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interact with the endogenous cannabinoid system, in turn causing biological effects. Two types 
of assays were conducted to confirm these interactions: competitive binding assay and GTPγS 
functional assay. A competitive binding assay is done to determine the binding affinity of a 
compound to each receptor. The competition is between the chosen cannabinoid and a labeled 
ligand, such as 3[H]- CP-55940. It is known that the tritiated-labeled ligand will tightly bind to 
each of the cannabinoid receptors; therefore, if a test compound shows affinity for the receptors, 
the amount of labeled ligand bound to the receptor will be low resulting in high binding affinity 
of the test compound. A compound showing strong binding affinity for either of the cannabinoid 
receptors, warrants further testing to determine the functional activity. 
Though several methods of ligand-receptor radioligand binding for cannabinoids have 
been published (Pertwee 1997) (Xiong, Cheng et al. 2011) (Thomas 1998), standardization 
within each laboratory is required for meaningful comparisons to be made between research 
groups. The experimental conditions for these assays are critical as minimal changes may lead to 
major variations in binding and functional values. When evaluating ligands at the cannabinoid 
receptors, factors such as lipophilicity, solubility, and purity should be carefully considered due 
to the sensitivity of the assays. Since cannabinoids are generally non-polar compounds, they 
have a tendency to stick to glass and plastic surfaces used in ligand-receptor assays. If the 
cannabinoids stick to the equipment used, this could lead to inaccurate results of ligand binding 
and function (Console-Bram Linda 2012).  
Silanization is a common technique used in laboratories to avoid cannabinoids sticking to 
glass and plastic. In addition to silanization, another technique is the use of Bovine Serum 
Albumin (BSA). BSA has been used in assays as a carrying agent and stabilizer for compounds 
with high lipophilicity. BSA is added to buffer recipes to create a reagent that can be absorbed 
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and utilized by cells (Kenna 1985). Buffer recipes for cannabinoid receptor assays have been 
optimized to include 50 mM Tris (23 mM Tris base and 27 mM Tris HCl to assist with pH), 154 
mM NaCl, 20 mM disodium ethylenediaminetetraacetic acid (EDTA), and 0.2% BSA. The 
buffer pH is then adjusted to 7.4 using sodium hydroxide or hydrochloric acid.  The use of this 
buffer and other optimized techniques, described below, allow for remarkable specific values to 
be obtained.  
To assess binding of compounds to the cannabinoid receptors, competition binding was 
performed following modifications to previously published methods (Pertwee 1997). 
Cannabinoid binding took place under the following conditions. The binding assays were 
performed with 100 µL of 0.5 nM 3H- CP-55940, 10 µL of 10 µM test compound (unless dose-
response then first well is 100 µM followed by appropriate dilutions), and 100 µL of 10 µg 
protein of membrane for a total assay volume of 210 µL. Binding was initiated by the addition of 
10 µg protein of CB1 or CB2 cell membranes. Assays were carried out at 37°C for 90 minutes 
before termination via rapid vacuum filtration through Whatman GF/C glass-fiber filters, 
presoaked with 0.3% BSA, using a Perkin Elmer 96-well Unifilter Harvester (Perkin Elmer Life 
Sciences Inc., Boston, MA, U.S.A.). Each assay plate was washed seven times with ice-cold 
wash buffer (same as assay buffer). Filters were allowed to dry overnight at room temperature 
(25°C) and then radioactive counts were extracted from the filters using a scintillation cocktail 
before quantification using a Perkin Elmer TopCount (Perking Elmer Life Sciences Inc., Boston, 
Mass. U.S.A). The cannabinoids that produced at least 50% displacement of the radioligand from 
specific binding sites were calculated using GraphPad Prism (GraphPad Software, San Diego, 
CA, U.S.A.) to obtain Ki and IC50 values.  
The objective while performing in vitro cell based binding assays is to achieve an 
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exceptional specific binding value. For the cannabinoid assays, total binding was defined as 
binding in the presence of 0.1% dimethylsulfoxide (DMSO). Nonspecific binding was the 
binding observed in the presence of 0.1 µM CP-55940. Specific binding was defined as the 
difference between total and nonspecific binding. The percent binding for each assay was found 
with the following formula: 
100 – (binding of compound – nonspecific binding) x 100/ specific binding 
The development and optimization of the cannabinoid receptor competitive binding assay led to 
consistent specific binding values of greater than 90%. 
c. GTPγS Functional Assay 
A functional assay determines whether the test compound is acting as an agonist, 
antagonist, or inverse agonist. As opposed to the binding assay, an in vitro functional assay is not 
based upon competitive binding, but rather a competitive saturable process that traces the 
amounts of guanosine triphosphate (GTP). When the cannabinoid membranes are not stimulated, 
there is a pool of guanosine diphosphate (GDP) associated with the receptors. Upon stimulation, 
there is dissociation of the G-protein from the receptor and bound GDP is exchanged for GTP. 
To monitor this response, 35S labeled GTP is added to the assay. Therefore, an increase in GTP is 
directly proportional to stimulation of the receptor by labeled ligand. An agonist compound is 
indicated by an increase in GTP (Kenakin 2002).  
There are several terms used when discussing the functional activity of a compound. 
Each compound that produces an effect may act a partial agonist, full agonist, inverse agonist, or 
neutral antagonist. Agonists that produce a reduced level of response are termed partial agonists. 
Though partial agonists may occupy all of the receptors, its ability to induce G protein-receptor 
coupling is reduced, resulting in submaximal activity. For instance, Δ9-THC binds tightly to the 
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CB1 and CB2 receptors; however, it has a functional Ki of approximately 300 nM, which means 
it is acting as a partial agonist, yet is still responsible for the psychoactive effects associated with 
Cannabis. A full agonist is defined as having the ability to bind to the receptor, and display 
maximal efficacy at that receptor (Brunton 2008).  
GTPγS Functional Assay
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Figure 3.2. Example of a partial agonist and full agonist in the GTPγS functional assay. 
While an agonist is said to increase endogenous agonist response, an antagonist results in 
the blocking of endogenous agonist response and causes lack of intrinsic activity. Antagonism is 
sometimes referred to as competitive antagonism because the compounds causing this effect bind 
to the same receptor site in which the endogenous agonists bind. To detect an antagonist in the 
functional assay, the compound must be tested in the presence of a known agonist at that specific 
receptor. Due to the competition of the agonist and antagonist for the same receptor site, the 
antagonist blocks the ability of the agonist to fully stimulate the receptor, thus resulting in a 
lesser value for the agonist (U'Prichard 1977). 
Another type of antagonist, also known as an inverse agonist, has the ability to reverse 
the biological effects associated with agonists at the cannabinoid receptors. This action occurs 
because affinity for the receptors is increased after uncoupling from G proteins. This type of 
activity was first observed in 1989 by Costa and Herz, which they described as a compound that 
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has “negative intrinsic activity.” It is known that of all the G protein-coupled receptor 
antagonists, approximately 85% are considered inverse agonists (Costa 1989). As seen with 
Rimonabant, compounds displaying inverse agonist activity may have promising therapeutic 
potential.  
GTPγS Functional Assay
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Figure 3.3. Example of an inverse agonist. 
The correlation between in vitro and in vivo bioassays begins with evaluation of 
functional data in vitro to predict pharmacological effects that may be seen in vivo. Functional 
activity was measured in CB1 and CB2 receptors using modifications to previously published 
methods (Xiong, Cheng et al. 2011). The use of cell lines is preferred for these assays over tissue 
homogenates because the signal-to-noise ratio is improved by overexpressing the receptors. The 
binding affinities were not used as a guide for this assay because dissociation between affinity 
and efficacy is not unusual for G protein-coupled receptors (Carlsson 2010). For putative 
agonists and inverse agonists, full concentration curves were constructed. In the case of putative 
antagonists, activity was confirmed by testing increasing concentrations of the compound 
together with a constant concentration of a known agonist, CP-55940. The antagonist blocks the 
ability of the agonist to fully stimulate the receptor, thus resulting in a right shift of the agonist 
EC50. 
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GTPγS functional assays were performed under slight modifications to previously 
published methods (Xiong, Cheng et al. 2011). The assay buffer for the GTPγS functional assay 
consisted of 50 mM Tris-HCl, 0.2 mM ethylene glycol tetraacetic acid (EGTA), 9 mM MgCl2, 
150 mM NaCl, and 1.4g BSA. Binding took place under the following conditions: 50 µL 
compounds diluted to the desired concentrations in the dose response curve were mixed with 20 
µg CB1 or CB2 membrane, 50 µM GDP, 0.5 nM 35S-labelled GTP, and 300 µL assay buffer for a 
total volume of 500 µL per well. Plates were incubated for 120 minutes at 37°C. The reaction 
was terminated via rapid vacuum filtration through Whatman GF/B filters using a Perkin Elmer 
96-well Unifilter Harvester (Perkin Elmer Life Sciences Inc., Boston, MA, U.S.A.). Each assay 
plate was washed four times with ice-cold wash buffer (10mM Tris-HCl, pH = 7.4). Filter plates 
were allowed to dry overnight at room temperature (25°C) and then radioactive counts were 
extracted from the filters using a scintillation cocktail before quantification using a Perkin Elmer 
TopCount (Perking Elmer Life Sciences Inc., Boston, Mass. U.S.A).  
Basal binding was defined as binding in the presence of assay buffer. Nonspecific 
binding was the binding observed in the presence of 40 µM unlabeled GTPγS salt. Emax binding 
was defined as binding in the presence of 1 µM CP-55940. Percent stimulation was measured by 
the following: 
((Binding of compound-nonspecific binding) / Emax)*100 
Ki and EC50 values were calculated using Graph Pad Prism (GraphPad Software, San Diego, CA, 
U.S.A.). Cannabinoids that show promising activity in the functional assay, whether acting as an 
agonist or antagonist, may be tested in vivo to determine pharmacological effects.  
C. Extraction, Isolation, Structure Determination 
The intensive process of using natural products as lead compounds in drug discovery 
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requires bioassay-guided fractionation, isolation, and structure elucidation followed by a large-
scale repetition for the isolated compounds with potential use. Over the past two decades, natural 
product research has been at a slow decline despite large amounts of success. Approximately 
63% of small-molecule new chemical entities introduced between 1981 and 2006 were natural 
products, semi-synthetic natural product analogues, or synthetic compounds based on natural 
product pharmacophore (Newman 2007). This decline in natural product chemistry is due to 
pharmaceutical industries using combinatorial chemistry and high-throughput screening 
(Paterson 2005). 
It was believed that pharmaceutical industries were going to shut down the use of natural 
product research with combinatorial chemistry and high-throughput screening; however, this is 
not the case. The industries found their methods not as successful as they hypothesized. Over one 
million compounds were synthesized for combinatorial libraries, but very few showed potential 
therapeutic activity. This was a mistake of the synthetic chemists who developed libraries based 
on accessibility and size instead of biologically relevant properties. It is critical for a library of 
compounds to contain chemical diversity, but it must also have “biological friendliness” and 
“drug-likeness” properties (Martin 2001). Even so, the few compounds that do result in hits have 
high potential for undesirable side effects (Paterson 2005). Thus, “a small collection of smart 
compounds may be more valuable than a much larger hodgepodge collection mindlessly 
assembled” (Borman 2002). 
Natural product compounds have several common characteristics that differs their 
activity from synthetic compounds. Although several natural products have simple structures, 
most are more complex and contain more stereogenic centers than synthetic compounds. Also, 
natural products contain more oxygen, hydrogen, carbon, and less nitrogen atoms than synthetic 
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medicinal compounds. Furthermore, it is common for natural products to not follow Lipinski’s 
rules. In fact, Lipinski’s fifth rule states that the first four rules do not apply to natural products. 
Natural product chemistry is rising again due to improvements in the methods of extraction, 
isolation, and structure elucidation (Clardy 2004).  
The concept of using natural products as a means for medicine is thriving in today’s 
research institutions. There are many methods that provide a way to extract, isolate, and 
determine the structure of novel compounds from plant material. Years of research have led to 
optimal methods in which the active compounds from Cannabis sativa have been extracted and 
purified. Once these compounds have been isolated, biological evaluation is critical for the 
success of novel medicines. However, since these methods are time consuming and strenuous, it 
is very difficult to obtain a sufficient amount of cannabinoids, especially minor cannabinoids in 
order to evaluate pharmacological effects (Galal 2009). 
a. Extraction 
To begin the extraction of compounds from Cannabis, the plant material is grown via 
proper cultivation in order to obtain a large amount of plant material. The Cannabis sativa plants 
were grown from high potency Mexican seeds in the marijuana plant garden at the University of 
Mississippi. Upon flowering, the male plants were removed from the field to avoid cross-
pollinations and only female plants were kept for further cultivation. Cuttings were made from 
selected female plants for further cultivation under a controlled environment. This environment 
consisted of a combination of 1000 Watt full spectrum metal highlight and sodium bulbs, 25°C 
temperature, 55% humidity, and a hot air suction fan about 3 to 4 feet between plants and bulbs 
to avoid heating from high intensity discharge bulbs. 
Once mature, Cannabis buds and leaves are picked and allowed an allotted time period to 
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dry. This may take several days since air-drying is the only process in which compounds will not 
decompose. Some cannabinoids are heat sensitive, therefore, using heat to dry the compounds 
may degrade many of the active compounds within Cannabis into non-active fractions, or a 
metabolite of the parent compound. When the buds and leaves have dried, using an organic 
solvent is the first step in the extraction process. In this case, the buds and leaves and are soaked 
in 100% hexanes overnight. Next, simple filtration using cotton is done in order to achieve only 
solvent containing cannabinoids. Furthermore, using a rotational evaporator under reduced 
pressure allows for obtainment of the extract. Using the extract, the next step is to fractionate 
using a vast array of solvent ratios. For example, eight different fractions are collected: 100% 
hexanes, 25% hexanes : 75% EtOAc, 50% hexanes : 50% EtOAc, 75% hexanes : 25% EtOAc, 
25% EtOAc : 75% MeOH, 50% EtOAc : 50% MeOH, 75% EtOAc : 25% MeOH, and 100% 
MeOH. These fractions are collected using vacuum liquid chromatography (VLC) over a one 
hour time period. Using this method of VLC allows for rapid and efficient separations, which 
results in saving time and money. In the non-polar solvent, 100% hexanes fraction, compounds 
such as waxes, sterols, and oils will be isolated. The diluted fractions containing a mixture of 
hexanes/EtOAc or EtOAc/MeOH will contain almost all of the major and minor cannabinoids 
from Cannabis sativa. Isolation from the polar solvent fraction, 100% MeOH, will afford 
compounds such as polyhexanes, salts, and sugars. 
b. Isolation 
Each fraction of the Cannabis extract may contain several compounds. In order to 
individually separate these compounds, numerous isolation techniques can be used. Three main 
column chromatography methods are used for the initial isolations: silica gel column 
chromatography, C18 column chromatography, and Sephadex LH-20 column chromatography. 
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Using silica or C18 affords pure compounds from a mixture of compounds based on differences 
in the polarity of functional groups; Sephadex LH-20 is a liquid chromatography medium used to 
separate compounds based on molecular weight. Variations of these column techniques are also 
used, such as an open column, flash chromatography, high-performance liquid chromatography, 
and solid phase extraction.  
An open column simply uses gravity to pull the liquid fraction through the column and 
into separate fractions. Flash chromatography is a very rapid form of column chromatography. It 
uses a smaller sized column along with an applied gaseous pressure from the top of the column 
allowing for rapid separation of compounds from a fraction. High-performance liquid 
chromatography (HPLC) is one of the most common methods of sample separation used. Today, 
HPLC is used for analysis of drugs in urine samples and measuring vitamin D levels in blood. 
This method of separation uses a pump that pushes samples through a column at very high 
pressure, and has a detector that identifies samples based on retention times. When dealing with 
smaller fractions, solid phase extraction is a commonly used technique. 
c. Structure Determination 
The final step in cannabinoid identification is to determine the structure of the isolated 
compound. Similar to isolation, there are many methods that can be used to determine the 
structure of a compound (s). The most commonly used method is gas chromatography (GC) with 
different detection methods, such as flame ionization detector  (FID) and mass spectrometry 
(MS). GC/MS is used frequently due to its ability to use small sample sizes and have good limits 
of detection. Alone, GC is a poor qualitative tool, but has good separating ability; MS is good for 
confirmation of peak identity, but difficult when using complex mixtures. Together, they have 
become the most used technique for the identification of cannabinoids due to ease and accuracy 
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(McNair 1992).   
The University of Mississippi has built a full library of cannabinoid data and is stored 
within each of the structure determining systems. With this said, GC/MS helps identify structures 
based on molecular weight and fragmentation. Also within the library, retention times are known 
for the cannabinoids that have been previously isolated and identified. Along with these 
methods, other methods such as infrared spectrometry (IR), nuclear magnetic resonance (NMR), 
high-resolution mass spectrometry (HRMS), x-ray crystallography, or ultra-violet (UV) detection 
are also used to aid in solving the structure of the isolated cannabinoid. The complete NMR 
assignments of major cannabinoids and flavonoids was published in a review in 2004 (Choi, 
Hazekamp et al. 2004). 
D. In Vivo Bioassays 
In vivo bioassays are used to determine the pharmacological effects of a potential 
therapeutic drug. The ability to use animal models allows scientists to know the complete effects 
of a potential drug, including beneficial and deleterious effects, route of administration, and dose 
level before going into human trials. Use of in vivo bioassays for cannabinoid research has 
contributed a major role to understanding their mechanism of action and potential as therapeutic 
drugs. In an attempt to understand the mechanism in which the endocannabinoid system can 
modulate pain, feeding, cardiovascular function, and other pharmacological functions, specific in 
vivo tests are performed to evaluate the actions that cannabinoid compounds are displaying 
within a test subject.  
a. Tetrad Assay 
In the late 1980s, Little and his colleagues began testing rodents treated with 
cannabinoids in a tetrad assay. The term tetrad describes a series of four different tests to help 
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evaluate the biological effects of a compound: 1) Spontaneous activity 2) Catalepsy 3) 
Hypothermia and 4) Analgesia. The spontaneous activity test allows a researcher to determine if 
the rodent is acting “lazy.” The rodent is placed in a box with perpendicular beams of light 
serving as gridlines. The test determines the amount of times the photobeams are broken in an 
allotted time period; an increase in the number of times broken correlates with a decrease in 
locomotor activity. Slight modifications of the ring test developed by Pertwee are used to 
determine if the drug causes cataleptic effects (Pertwee 1972). For this assay, a rodent is placed 
on a bar elevated off the ground surface. If the rodent remains immobile, it is considered 
cataleptic. Hypothermia, also know as the rectal temperature assay, is simply a measure of the 
rodents rectal temperature after the drug has been administered. For the last part of the tetrad 
assay, there are two different methods of testing for analgesic effects, hot-plate assay and tail-
flick assay. In the hot-plate assay, a rodent is placed upon a hot plate and the time it takes for the 
rodent to react, usually a small jump, is recorded. In the tail-flick assay, the rodent is 
immobilized and a high temperature beam of light is sporadically placed on the tail. If the rodent 
feels pain, it will move its tail either left or right, hence the name tail-flick (Little 1988).  
b. Feeding 
It is known that the endocannabinoid system regulates appetite in humans; however, the 
mechanism of action is not well understood. The attempt to dissect the role of the 
endocannabinoid system in appetite regulation has led to novel therapies for anorexia and 
obesity. The interaction of compounds with the CB1 receptor is the cause of appetite 
stimulation/reduction seen with the endocannabinoid system. Agonists at the CB1 receptor are 
appetite stimulants, while inverse agonists at CB1 are appetite suppressants (Berry and 
Mechoulam 2002).  
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To determine the pharmacological effects of cannabinoids associated with appetite, in 
vivo feeding studies are conducted. The test compound is administered via intraperitoneal 
injection at specific doses. Drug administration occurs daily, along with monitoring of food 
intake. The animals that consume an increased amount of food in comparison to the placebo help 
establish that the compound is acting as an agonist at CB1. If food consumption is minimal, it is 
believed that the test compound is acting as an antagonist/inverse agonist at CB1. Using these in 
vivo animal models has led to the marketing of compounds that cause pharmacological effects 
associated with an interaction at the CB1 receptor.  
i. Agonist at CB1 
The use of Cannabis as an appetite stimulant dates back to the mid 1800s (Donovan 
1845). Reports indicate that Cannabis enhanced appetite, and that it “restored the ability to 
appreciate food” (Birch 1889). The finding that Δ9-THC, a partial agonist at CB1, is the active 
ingredient in Cannabis caused researchers to evaluate its direct effects on appetite. The results 
indicate that Δ9-THC causes appetite stimulation by acting as an agonist at the CB1 receptors. 
The use of Δ9-THC as an appetite stimulant is currently available to help treat patients suffering 
from anorexia and wasting syndrome associated with AIDS (Beal 1995), elderly (Roubenoff 
1999), and cancer (Balog 1998).  
ii. Inverse Agonist at CB1 
Conversely, using cannabinoid antagonists/inverse agonists has potential therapeutic 
benefit for the treatment of obesity. Rimonabant was the first marketed CB1 selective 
cannabinoid used for the treatment of obesity. It acts an inverse agonist at the CB1 receptor and 
therefore does not cause psychoactivity like agonists at CB1. Rimonabant causes a decrease in 
appetite stimulation, which in turn aids in the treatment of obesity. However, after only three 
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years on the market Rimonabant was removed in 2009 due to side effects associated with 
depression and suicide risk (Fong and Heymsfield 2009). 
c. Cardiovascular 
Most recent research has focused on the actions of cannabinoids on the central nervous 
system, now attention is shifting towards the peripheral effects cannabinoids possess including 
the cardiovascular effects. The in vivo studies of cannabinoids on the cardiovascular system have 
shown conflicting results indicating both increases and decreases in blood pressure (Stark 1980). 
Currently, a common underlying theme is that exogenously administered cannabinoids to 
animals under anesthesia cause hypotension and bradycardia. These effects are thought to be 
entirely CB1 receptor-mediated, as this response is absent in CB1 receptor knockout mice 
(Ledent 1999). In vivo hemodynamic studies are used to determine the actions of cannabinoids 
on cardiovascular effects. The use of these studies measures systolic and diastolic pressures, 
mean arterial pressure, heart rate, and contractility (Levy 1972). The fact that cannabinoids 
exhibit cardiovascular effects may begin to explain their participation in shock, though the exact 
role of the endocannabinoids on the vascular system remain unknown (Randall 2002).  
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CHAPTER IV 
RESULTS 
The development of in vitro bioassays to determine ligand-receptor interactions of 
compounds for the CB1 and CB2 receptors is a necessary tool in the development of an accurate 
structure-activity relationship (SAR). Since the three-dimensional structures and amino acid 
residues at active sites of cannabinoid receptors have not been characterized, information about 
structural requirements for ligand-receptor interactions is obtained through development of 
different molecular probes (Khanolkar 2000). Along with in vitro bioassays, ligand-receptor 
interactions can be determined using receptor mutants (McPartland 2003) and computer 
modeling (Reggio 1999).  
In order to gain a better understanding of phytocannabinoids and their relationship 
towards the cannabinoid receptors, a SAR was developed based on in vitro binding affinity and 
functional activity. The intent of developing a SAR for cannabinoid receptor ligands is to 
develop potential therapeutic compounds that are void of some of the unwanted side effects 
associated with Cannabis. Using the relationships seen with this study of novel 
phytocannabinoids, known phytocannabinoids, and synthetic derivatives of phytocannabinoids, 
will aid in developing lead compounds to potentially treat many of the diseases associated with 
the regulation of the endocannabinoid system.  
The objective of novel therapeutics associated with endocannabinoid regulation is to rid 
the unwanted side effects, such as psychoactivity. Stimulation of CB1 receptors by an agonist 
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causes the psychoactivity seen with Cannabis use. Whether for recreational or medicinal use, 
stimulation of CB1 receptors has shown to cause euphoria. Though most believe this is an 
“innocent high,” studies show that administration Cannabis influences reward pathways through 
the dopaminergic system leading to addiction. In fact, Δ9-THC activates dopaminergic pathways 
in similar ways to heroin (Tanda 1997). Similar studies conclude that Cannabis use and the 
endocannabinoid system serve as a link to schizophrenia (Degenhardt 2006). Current research to 
potentially develop safe, non-psychoactive therapeutic drugs is focusing on fully understanding 
the mechanism of action in which the cannabinoid receptors and endocannabinoid system work.  
There are several methods to avoid the psychoactivity associated with CB1 receptors. 
Some examples would be to develop compounds that activate only CB2 receptors or target the 
CB1 and CB2 receptors located outside of the central nervous system. Developing selective 
ligands for CB2 have the potential to be a therapeutic treatment for neurodegenerative, 
cardiovascular, liver, kidney, bone, autoimmune, pain, cancer, bone, and skin diseases (Pacher 
2011). Recent reports indicate that if compounds do not penetrate the blood-brain-barrier then 
the possibility of psychological side effects is significantly reduced (Nogueiras 2008).  Thus, the 
development of cannabinoid receptor SAR has great potential in determining lead compounds 
with potential therapeutic use through effects on the endocannabinoid system.  
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A. Δ9-Tetrahydrocannabinol 
 
 
Figure 4.1. Chemical structures of Δ9-THC used in the SAR study. 
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Compound Binding Affinity (nM) Functional Activity (nM) 
 CB1 CB2 CB1 CB2 
1 18.60 ± 4.00 42.25 ± 9.11 268.80 ± 36.09 327.40 ± 43.99 
16 1,292.00 ± 89.03 1,650.00 ± 
163.14 
> 10,000 > 10,000 
17 22.67 ± 5.88 105.30 ± 21.54 > 10,000 > 10,000 
18 3,293.00 ± 
445.43 
2,771.00 ± 
488.00 
4,425.00 ± 
1,229.15 
7,264.00 ± 
1,565.31 
19 5,668.00 ± 
1,324.98 
2,143.00 ± 
353.46 
> 10,000 > 10,000 
20 117.60 ± 16.32 129.30 ± 13.23 > 10,000 > 10,000 
21 > 10,000 > 10,000 > 10,000 > 10,000 
22 1,906.00 ± 
578.68 
3,219.00 ± 
876.94 
1,884.00 ± 
494.88 
8.25 ± 1.11 
23 65.61 ± 16.47 88.45 ± 19.12 2,535.00 ± 
340.75 
> 10,000 
Table 4.1. Binding affinities and functional activities of Δ9-THC derivatives for 
human CB1 and CB2 receptors. All compounds acted as agonists in the functional 
assay. 
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Figure 4.2. Competitive binding curves for compound 20. 
Since 1964, Δ9-THC (1) has been classified as the primary psychoactive constituent of 
Cannabis (Gaoni and Mechoulam 1964). Since then, it has served as lead compound for the 
synthesis of hundreds of analogs that have potential as pharmacological agents. It binds to and 
activates both cannabinoid receptors, CB1 and CB2. Δ9-THC binds tighter to CB1 than CB2 with 
Ki values of 18.60nM and 42.25nM, respectively. Functionally, it acts as a partial agonist at both 
CB1 and CB2 receptors with Ki values of 268.80nM and 327.40nM, respectively. The 
functionally inactive acid precursor of Δ9-THC, Δ9-tetrahydrocannabinolic acid (16), has 
significantly decreased binding affinity for both cannabinoid receptors.  
Since the early 2000s, the lipophilic side chain at C-3 has been investigated for its role 
with cannabinoid ligand potency and selectivity. For Δ9-tetrahydrocannabivarin (17), the 
shortening of the C-3 side chain of Δ9-THC from a 5-carbon (pentyl) chain to a 3-carbon 
(propyl) chain retains binding affinity. Ultimately, a 1,1-dimethyl-heptyl side chain has resulted 
in the best binding affinity and functional activity (Liddle 2001). Accordingly, the reduction of 
the C-3 side chain in compound 17 did not functionally activate the cannabinoid receptors. 
It is possible that some compounds may bind tightly to the cannabinoid receptors, 
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however, they may not functionally activate these receptors. For instance, compounds 17 and 10-
α-OH-Δ9,11-hexahydrocannabinol (20) bind to both CB1 and CB2 receptors, yet they do not 
functionally activate either of these two receptors. When comparing 20 and 10-β-OH-Δ9,11-
hexahydrocannabinol (21), the only structural difference is the hydroxyl substitution in the C-10 
position. The α-OH substitution displays approximately 5-fold weaker binding affinity for CB1 
and CB2 when compared with Δ9-THC; however, it still displays moderate nanomolar binding 
affinity. On the other hand, the β-OH substitution at C-10 does not display binding affinity for 
either of the cannabinoid receptors. Finally, the presence of the hydroxyl group in the C-10 
position, whether α or β, completely abolishes functional activity for both receptors.  
Two new isolates from Cannabis, 8-α-OH-Δ9-THC (22) and 8-β-OH-Δ9-THC (23), have 
the Δ9-THC core structure with the addition of a hydroxyl group at C-8 (unpublished). The 
results indicate that a hydroxyl substitution in the C-8 position of Δ9-THC plays a large role in 
ligand binding affinity. The β-OH of 23 retained strong binding affinity for CB1 and CB2 and 
the α-OH of 22 displayed much weaker binding affinity to both cannabinoid receptors. 
Functionally, both compounds acted as weak agonists for CB1. Interestingly, compound 22 
displayed 8.25nM functional activity for CB2. This shows functional preference over the β-OH 
of 23 for the CB2 receptor. The result of the α-OH location shows that it is critical for CB2 
functional activity, and displays preference over CB1. The significance in displaying preference 
for one receptor is the ability to retain the positive pharmacological effects associated with 
cannabinoid receptor activation without having negative side effects. The ability of 22 to display 
strong functional activity only for CB2 has the potential to aid with pain and inflammation 
without causing psychoactive effects associated with stimulation of CB1 receptors. Thus, this 
compound has the potential to be a new therapeutic for non-addictive pain management.  
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B. Δ8-Tetrahydrocannabinol 
 
 
Figure 4.3. Chemical structures of Δ8-THC used in the SAR study. 
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Compound Binding Affinity (nM) Functional Activity (nM) 
 CB1 CB2 CB1 CB2 
5 78.11 ± 5.52 12.18 ± 2.01 5,820.00 ± 
782.41 
524.50 ± 70.54 
24 830.10 ± 94.40 3,274.00 ± 
515.14 
916.10 ± 
235.88 
9,999.00 ± 
2,777.17 
25 31.86 ± 6.65 30.85 ± 4.24 > 10,000 2,622.00 ± 
352.72 
26 4,034.00 ± 
956.11 
107.50 ± 19.08 49.21 ± 11.34 142.90 ± 29.86 
27 223.60 ± 34.69 170.90 ± 32.00 179.70 ± 34.01 476.80 ± 37.23 
28 > 10,000 720.50 ± 
122.29 
> 10,000 504.40 ± 51.63 
29 3,828.00 ± 
686.67 
414.20 ± 39.39 730.30 ± 
120.90 
52.99 ± 10.62 
30 1,812.00 ± 
245.35 
531.30 ± 24.13 5,055.00 ± 
1,512.03 
2,049.00 ± 
300.80 
Table 4.2. Binding affinities and functional activities of Δ8-THC analogs for human 
CB1 and CB2 receptors. All compounds acted as agonists in the functional assay. 
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Figure 4.4. Competitive binding and functional curves for compound 29. 
Δ8-THC (5) is the more stable regioisomer of Δ9-THC (Galal 2009). It has a similar 
pharmacological profile to Δ9-THC with slightly weaker activity for CB1 and CB2 (Pertwee 
2005). In comparison to 5, only one compound, 10-α-OH-Δ8-THC (25), displayed better binding 
affinity for CB1 with a Ki of 31.86nM. In the Δ8-THC class of compounds, 5, 10-β-OH-Δ8-THC 
(24), and 25 are isolated from high potency Cannabis sativa L., and 2-nitro-Δ8-THC, 2,8-dinitro-
Δ8-THC, 2-dimethylamino-Δ8-THC, 2-dibutylamino-Δ8-THC, 2-dihexylamino-Δ8-THC (26-30) 
are semi-synthetic analogs of Δ8-THC (unpublished). Compounds 24 and 25 contain a hydroxyl 
group, β -OH and α-OH, respectively, present in the C-10 position. The hydroxy substitution 
influences binding affinity such that the α-OH of compound 25 displays strong binding affinity 
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for both cannabinoid receptors. The β-OH of 24 also binds to CB1 and CB2, though not as 
tightly. Additionally, the β-OH of 24 warrants significantly increased functional activity for CB1 
over the parent molecule, Δ8-THC, and the α-OH substituted compound, 25.  
The addition and location of different nitrogen containing functional groups plays a role 
in receptor binding and activity. Depending upon the synthesized location of a nitro group, 
binding affinity for either CB1 or CB2 may be preferred. Addition of a nitro group in the C-2 
position of Δ8-THC shows preferential binding for CB2 with a Ki of 107.50nM. Addition of 
another nitro group at C-8 causes activation of CB1 receptor binding sites with approximately 
200nM affinity. Looking at all of the semi-synthetic derivatives of 5, it is clear that nitrogen 
substitutions at the C-2 position do no play a major role in CB2 receptor binding. However, 
addition of a nitrogen-containing group in the C-8 position significantly increases binding 
affinity of C-2 nitrogen substituted Δ8-THC compounds for the CB1 receptor. 
The addition of a nitro group in the C-2 position of 26 increased functional activity for 
CB1 and CB2 with Ki values of 49.21nM and 142.90nM, respectively. With a nitro group at C-2 
and the addition of another nitro group at C-8, compound 27 displayed slightly stronger 
functional activity for both CB1 and CB2 receptors compared to Δ8-THC.  
For compounds 28-30, three different nitrogen-containing substitutions were synthesized 
that only differed in the attached alkyl chain length: dimethyl, dibutyl, and dihexyl, respectively. 
Interestingly, these substitutions showed preferential binding for the CB2 receptor. Functionally, 
the results varied with 29 having the best functional activity for CB1 and CB2, 730.30nM and 
52.99nM, respectively. In conclusion, it seems that an α-OH substitution at C-10 provides the 
best binding affinity, and a nitrogen substitution in the C-2 position yields the best functional 
activity for the cannabinoid receptors. 
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C. Cannabinol 
 
 
Figure 4.5. Chemical structures of cannabinol used in the SAR study. 
Compound Binding Affinity (nM) Functional Activity (nM) 
 CB1 CB2 CB1 CB2 
8 75.29 ± 4.02 73.21 ± 4.00 307.30 ± 29.14 289.70 ± 38.94 
31 8,063.00 ± 
1,986.65 
11.47 ± 1.97 1,438.00 ± 
399.58 
5,099.00 ± 
725.25 
32 565.60 ± 138.65 4,780.00 ± 
331.00 
> 10,000 > 10,000 
Table 4.3. Binding affinities and functional activities of Cannabinol analogs for 
human CB1 and CB2 receptors. All compounds acted as agonists in the functional 
assay. 
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Figure 4.6. Competitive binding and functional curves for compound 8. 
Similar to Δ9-THC and Δ8-THC, cannabinol (8) is another psychoactive constituent 
isolated from Cannabis. It is a metabolite of Δ9-THC and results in an aromatized A ring 
(McCallum 1975). The aromatization of this ring causes slightly weaker binding affinity and 
functional activity than Δ9-THC. A novel phytocannabinoid containing the cannabinol-base 
structure displayed selective binding affinity for CB2 in the low nanomolar range, 11.47nM. This 
isolate, 8-OH-cannabinol (31), contains a hydroxyl group at the C-8 position of cannabinol. 
Similarly to Δ9-tetrahydrocannabivarin, analysis of cannabivarin (32) revealed that a pentyl side 
chain at C-3 is critical for retaining binding affinity and functional activity at both cannabinoid 
receptors.  
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D. Cannabigerol 
 
 
Figure 4.7. Chemical structures of cannabigerol used in the SAR study. 
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Compound Binding Affinity (nM) Functional Activity (nM) 
 CB1 CB2 CB1 CB2 
3 3,090.00 ± 
583.22 
2,919.00 ± 
752.43 
> 10,000 1,158.00 ± 
221.81 
33 4,526.00 ± 
953.53 
> 10,000 182.50 ± 32.09 118.10 ± 27.15 
34 > 10,000 4,718.00 ± 
87.35 
1,192.00 ± 
330.82 
> 10,000 
35 > 10,000 3,989.00 ± 
772.52 
235.40 ± 51.21 1,572.00 ± 
376.11 
36 1,409.00 ± 
162.19 
388.60 ± 67.00 618.60 ± 106.90 1,743.00 ± 
443.73 
37 > 10,000 > 10,000 > 10,000 2,592.00 ± 
519.51 
Table 4.4. Binding affinities and functional activities of Cannabigerol analogs for 
human CB1 and CB2 receptors. All compounds acted as agonists in the functional 
assay. 
 
Cannabigerol (3) is a non-psychoactive constituent of Cannabis (Izzo 2009), which lacks 
the dibenzopyran moiety seen in Δ9-THC. Though isolated from Cannabis, cannabigerol acts as 
an α2-adrenergic receptor agonist and 5-HT1A receptor antagonist (Cascio 2010). Of the six 
cannabigerol-type compounds isolated, only one displayed noteworthy binding affinity for either 
CB1 or CB2 receptors. This compound, 4-OH-5-acetoxy-cannabigerol (36), contains an acetyl 
substitution off the hydroxyl group at C-5, and has a binding affinity of 388.60nM for the CB2 
receptor.  
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Functionally, several compounds warranted notable activity at CB1 or CB2 receptors. 
The acid precursor of cannabigerol, cannabigeric acid (33), acts as an agonist for CB1 and CB2 
receptors with Ki values of 182.50nM and 118.10nM, respectively. Methoxy-cannabigerol (35) 
and 36 act as partial agonists for the CB1 receptor with Ki values of 235.40nM and 618.60nM, 
respectively. It is also important to note that the epoxide functional group present in the aliphatic 
side chain of 6,7-epoxy-cannabigerol (34) abolished CB2 functional activity.  
E. Flavonoids 
 
 
Figure 4.8. Chemical structures of flavonoids used in the SAR study. 
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Compound Binding Affinity (nM) Functional Activity (nM) 
 CB1 CB2 CB1 CB2 
12 559.50 ± 121.33 2,930.00 ± 
752.23 
1,155.00 ± 
370.63 
368.10 ± 51.46 
13 9,550.00 ± 
1,588.00 
> 10,000 103.70 ± 12.39 230.70 ± 33.06 
14 1,094.00 ± 
213.73 
1,361.00 ± 
192.88 
98.69 ± 25.15 51.64 ± 9.34 
15 5,040.00 ± 
1,134.43 
9,799.00 ± 
2,344.00 
2,303.00 ± 
710.03 
2,581.00 ± 
634.04 
Table 4.5. Binding affinities and functional activities of flavonoid analogs for 
human CB1 and CB2 receptors. All compounds acted as inverse agonists in the 
functional assay. 
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Figure 4.9. CB1 functional curves for compounds 12-15. 
The flavonoids isolated from Cannabis are not considered cannabinoids since they do not 
contain the C21 terpenophenolic base structure. The four flavonoids tested, cannflavin A (12), 
cannflavin B (13), cannflavin C (14), and 5,7,4’-trihydroxy-6-prenyl-flavone (15), showed 
moderate to weak binding affinity and strong to moderate functional activity. Since these 
compounds are not cannabinoids, it was expected that these compounds would not bind to the 
cannabinoid receptors. This hypothesis was proved wrong as these compounds displayed both 
binding affinity and functional activity. The binding affinity seen with the flavonoids is most 
likely due to the similarities it shares with Δ9-THC. For instance, they both contain lipophilic 
chains that are known to increase binding affinity. Also, they both contain a pyran functional 
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group and a phenolic hydroxy. These three major functional groups may be the reason that 
flavonoids bind to both cannabinoid receptors. As seen with cannflavins A and C, longer 
lipophilic chains are critical for binding affinity at CB1 and CB2 receptors.  
Dissociation between binding affinity and functional activity is not unusual for G protein-
coupled receptors (Carlsson 2010). The flavonoids showed strong inverse agonist functional 
activity for both cannabinoid receptors, CB1 and CB2. Cannflavin C displayed the most potent 
ability to reverse efficacy for CB1 and CB2 with Ki values of 98.69nM and 51.64nM, 
respectively. A significant loss of functional activity is present with compound 15. This loss of 
activity could correlate to the absence of the methoxy group in the C-3’ position.  
The importance of compounds acting as inverse agonists at the cannabinoid receptors is 
critical for the success of novel therapeutic drugs. For example, Rimonabant is a selective CB1 
inverse agonist that was marketed for the treatment of obesity. Although it has been removed 
from the market because of psychological side effects, it has been a strong lead compound for 
the novel treatments of obesity (Colombo 1998). The natural occurring flavonoids in Cannabis 
may potentially be used a lead treatment for obesity that could lack the undesirable psychological 
effects, such as suicidal thoughts.  
Furthermore, these four flavonoids act as inverse agonists for the CB2 receptor as well. 
Inverse agonist activity at CB2 has shown broad effects on cellular protein phosphorylations in 
human monocytes. This has shown to modulate bone damage and block encephalomyelitis in rats 
(Lunn 2008). Thus, a compound displaying inverse activity at CB2 has the potential to become a 
novel treatment for pain and inflammation associated with multiple sclerosis (Buccellato 2011).  
F. Cannabichromanone 
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Figure 4.10. Chemical structures of cannabichromanone used in the SAR study. 
Compound Binding Affinity (nM) Functional Activity (nM) 
 CB1 CB2 CB1 CB2 
38 3,470.00 ± 
601.32 
4,371.00 ± 
1,119.67 
965.30 ± 
268.28 
> 10,000 
39 8,681.00 ± 
1,404.00 
5,789.00 ± 
685.24 
483.20 ± 
121.76 
138.50 ± 36.76 
40 7,117.00 ± 
1,090.24 
2,828.00 ± 
569.98 
8.73 ± 0.89 3,945.00 ± 
1,106.77 
Table 4.6. Binding affinities and functional activities of Cannabichromanone 
analogs for human CB1 and CB2 receptors. All compounds acted as agonists in the 
functional assay. 
 
Currently, there is little known about the pharmacological role that cannabichromanone 
isolates may exhibit. All three compounds evaluated in this study were isolated in 2008 by 
ElSohly and colleagues at the University of Mississippi. The isolated phytocannabinoids were 
named cannabichromanone B (38), cannabichromanone C (39), and cannabichromanone D (40) 
due to their structure similarity of previously isolated cannabichromanone A. Several of the 
O
OO
R
R1
R2
38: R = H 39: R = H
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cannabichromanone-type compounds displayed antimalarial and antileishmanial activity. 
Furthermore, these compounds all displayed strong anti-oxidant properties (Ahmed 2008).  
The in vitro binding and functional studies show that the cannabichromanone derivatives 
display a variety of activity at both cannabinoid receptors. It is worthy to note that 
cannabichromanone D has a slightly different structure than the other derivatives as the aliphatic 
chain cyclizes and forms a third ring with the phenolic hydroxyl. Interestingly, 
cannabichromanone D displayed selectivity for the CB1 receptor in the GTPγS functional assay, 
acting as a full agonist with a Ki value of 8.73nM. Though not as potent as cannabichromanone 
D, cannabichromanone B also displayed preferential activity for the CB1 receptor, acting as an 
agonist with a Ki value of 965.30nM. Finally, cannabichromanone C displayed moderate 
functional activity for the CB1 and CB2 receptors with Ki values of 483.30nM and 138.50nM, 
respectively.  
Though the cannabichromanone derivatives have not been evaluated for their ability to 
induce psychoactivity, it is safe to say that these compounds will induce psychoactivity, 
depending on the dose, because of their ability to functionally stimulate the CB1 receptors.  
G. Cannabidiol 
 
 
Figure 4.11. Chemical structures of cannabidiol used in the SAR study. 
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Compound Binding Affinity (nM) Functional Activity (nM) 
 CB1 CB2 CB1 CB2 
2 151.90 ± 28.88 4,582.00 ± 
613.42 
1,469.00 ± 
197.44 
104.20 ± 14.01 
41 503.00 ± 58.13 3,970.00 ± 
976.84 
> 10,000 3.63 ± 0.79 
Table 4.7. Binding affinities and functional activities of Cannabidiol analogs for 
human CB1 and CB2 receptors. All compounds acted as agonists in the functional 
assay. 
 
Cannabidiol (2) is one of the major, non-psychotropic cannabinoids isolated from 
Cannabis sativa (Grlic 1976). It was first isolated in 1940 (Adams 1940), but the exact structure 
was not determined until 1963 (Mechoulam and Shvo 1963). Cannabidiol has been the most 
studied non-psychoactive phytocannabinoid because of its potential as a therapeutic agent for 
many diseases. The scientific literature shows that cannabidiol may aid in inflammation (Malfait 
2000), nausea, sedation (Grotenhermen 2002), neuroprotection (Hampson 1998), cancer cell 
growth (McAllister 2007), and schizophrenia (Zuardi 2006). Interestingly, studies have shown 
that the anxiety produced from Δ9-THC can be blocked with the administration of cannabidiol 
(Zuardi 1982). Furthermore, a combination of Δ9-THC and cannabidiol are now marketed in 
Canada under the trade name Sativex, which is used to alleviate pain associated with Multiple 
Sclerosis (Barnes 2006). The potential that rises from the use of cannabidiol as a therapeutic drug 
is of importance in today’s society.  
The low functional activities of cannabidiol and cannabidivarin (41) for the CB1 receptor 
supplement that these compounds do not display psychotropic effects. The positive therapeutic 
effects of cannabidiol are seen through its interaction with the CB2 receptor. Cannabidiol acts as 
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an agonist and has preference for the CB2 receptor. Similarly, cannabidivarin, acting as a full 
agonist, has selectivity for the CB2 receptor. The strong Ki value of these two compounds for the 
CB2 receptor correlate with studies that discuss the potential for selective CB2 agonists as 
treatments for pain and inflammation associated with numerous CNS diseases (Mechoulam, 
Peters et al. 2007). 
H. Volatile Oil 
The constituents of Cannabis have been commonly studied and evaluated for their 
pharmacological effects as pure compounds. Currently, there are new approaches associated with 
the evaluation of compounds from Cannabis. It is believed that the mixture of cannabinoids, 
terpenoids, and flavonoids may have a synergistic relationship for producing therapeutic effects 
since many unwanted side effects associated with pure compounds result upon administration 
(Hazekamp 2009). It is known that terpenoids posses a wide range of biological effects such as 
chemopreventitive effects, skin penetration enhancement, antimicrobial, antifungal, antiviral, 
anti-hyperglycemic, anti-inflammatory, and antiparasitic activities (McPartland 2001). 
Therefore, it is of interest to identify the terpenes within Cannabis for potential therapeutic leads.  
The cannabinoids isolated from Cannabis sativa are odorless compounds; however, the 
terpenes present in the volatile oil of Cannabis provide its unique aroma. The volatile oil contains 
a large percentage of terpenoids, monoterpenes and sesquiterpenes, with monoterpenes 
dominating the percentage. There is approximately 90% monoterpenes, 7% sesquiterpenes, and 
1% other chemical classes such as simple ketones and esters. Generally, the most abundant 
terpenoid associated with the volatile oil of Cannabis is myrcene. The scientific literature 
indicates that depending upon the life cycle of the plant, distillation method, drying, and storage, 
percentages of specific terpenoids may be significantly increased or decreased. For instance, in 
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1996 Ross and ElSohly published an article discussing the composition of fresh and air-dried 
buds of Cannabis sativa. The results indicated that the method of drying the buds does not alter 
chemical composition of the volatile oil, but the length of storage of the dried buds does cause a 
decrease of terpenoids in the volatile oil (Ross 1996).  
Δ9-THC is known to cause negative psychological reactions such as anxiety. The 
scientific literature reports that the terpenoids associated with Cannabis may alleviate the 
negative effects because of their ability to act as sedatives and antidepressants (Brenneisen 
2010). To date, there have been no reports of the volatile oil of Cannabis and its ability to bind 
the human cannabinoid receptors. Here we present seven different fractions from the crude 
volatile oil of high potency Cannabis sativa for their in vitro ability to bind to human CB1 and 
CB2 receptors. Due to the sensitivity of the bioassays, the volatile oil fractions containing Δ9-
THC are expected to show a high binding percentage for CB1 and CB2 receptors. Interestingly, 
some of the fractions that do not contain Δ9-THC also showed binding to the cannabinoid 
receptors.  
All of the components from high potency Cannabis sativa were extracted from the air-
dried buds using hexanes and methanol solvents. The crude Cannabis extract was heated to 
120°C for approximately two hours in order to decarboxylate the inactive cannabinoid acids into 
their respective active state. Finally, the extract was then subject to vacuum distillation using a 
Kugelrohr in order to prepare the crude volatile oil. The volatile oil of Cannabis accounts for 
approximately 10% total weight of the dried buds. An initial cannabinoid primary screen 
indicated that the volatile oil had significant binding affinity to both CB1 and CB2 receptors. 
Using silica gel column chromatography for separation, seven different fractions of the volatile 
oil were evaluated for their ability to bind at CB1 and CB2 receptors (Table 4.8).   
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Fraction CB1 % Binding CB2 % Binding 
Si-A 39.2 1.6 
Si-B 36.8 12.0 
Si-C 78.6 94.1 
Si-D 79.2 89.3 
Si-E 86.0 78.3 
Si-F 50.6 45.0 
Si-G 39.1 29.7 
Table 4.8. CB1 and CB2 percent binding of seven different fractions from the 
volatile oil of Cannabis. 
 
The fractions displaying greater than 60% binding for CB1 and CB2 were deemed active 
fractions: Si-C, Si-D, and Si-E. Next, using gas chromatography with flame ionization detection 
(GC-FID) and gas chromatography with mass spectrometry (GC/MS), the major components, 
retention times, and percentage of compound within each fraction was determined. Table 4.9 
displays the major components for each of these fractions.  
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Table 4.9. Major components, retention times (TR), and percentages of components within the 
volatile oil of high potency Cannabis sativa. 
To further support the hypothesis that those fractions containing Δ9-THC will be active, 
Si-C and Si-D both contain Δ9-THC and resulted as active fractions. Although these fractions 
showed activity, further analysis of these fractions was not performed since both contain Δ9-
THC. Interestingly, Si-E also displayed binding activity for the cannabinoid receptors and does 
not contain Δ9-THC. Therefore, the major components in Si-E, that were isolated or available for 
purchase, were tested to potentially determine which compound (s) was responsible for the 
activity (Figure 4.8). Table 4.10 shows the CB1 and CB2 percent binding for each of the pure 
compounds from Si-E. 
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Figure 4.12. Chemical structures of pure compounds in Si-E 
 
Compound CB1 % Binding CB2 % Binding 
p-cymen-8-ol -22.6 -14.4 
caryophyllene oxide -27.4 -13.1 
cannabinol 82.6 89.8 
pulegone -6.0 -9.6 
Table 4.10. CB1 and CB2 percent binding of the pure compounds from Si-E. 
Note: not all major components were tested for CB1 and CB2 binding. 
Cannabinol as a pure compound displayed a high percent binding for CB1 and CB2. 
Furthermore, fractions Si-E, Si-F, and Si-G all contained a small percentage of cannabinol, 
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1.80%, 0.92%, and 2.13%, respectively. It is critical to note that the trace amounts of cannabinol 
are not responsible for the activity seen with fraction Si-E. If cannabinol were responsible for the 
activity associated with Si-E, fraction Si-G would have also shown activity since it has a slightly 
greater amount, 2.3%, than Si-E. Therefore, the minor and major components in fraction Si-E are 
acting synergistically to produce its effects on the cannabinoid receptors.  
Using SAR based on in vitro binding affinity and functional activity of compounds 
isolated from high potency Cannabis sativa has the potential to develop a lead compound to be 
further pursued in its path to becoming a therapeutic drug for the treatment of many 
physiological and pathological diseases associated with the cannabinoid receptors. There are 
three possible lead compounds from this study, 8-α-OH- Δ9-THC, 2-dibutylamino-Δ8-THC, and 
cannabidivarin, which can be further pursued by synthesizing derivatives to potentially increase 
potency and selectivity for CB2.  
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CHAPTER V 
CONCLUSION 
A. Summary 
Cannabis has been around for thousands of years and has been used for recreation, 
medicine, and fiber. Over 400 compounds have been isolated from Cannabis sativa with 
approximately 100 being cannabinoids. Of these 100 compounds, Δ9-THC has been determined 
as the primary constituent, which also is responsible for inducing psychoactivity. Along with Δ9-
THC, cannabidiol has been studied in depth for its therapeutic effects. This has currently been 
the focus of many researchers since cannabidiol does not cause psychotropic effects. The 
objective is to develop a drug that acts in a similar manner to Cannabis that lacks the unwanted 
side effects. 
G protein-coupled receptors are the largest superfamily among all human receptors. They 
are said to be responsible for mediating a variety of physiological and pathological processes. 
These receptors play an important role in drug discovery and development because they can be 
used as drug targets for potential therapeutic agents. It is known that approximately 27% of drugs 
approved by the Food and Drug Administration target G protein-coupled receptors. The 
cannabinoid receptors belong the large family of G protein-coupled receptors and play an 
important role in a variety of processes including pain, appetite, addiction, neurodegeneration, 
metabolic regulation, anxiety, cancer, and immune function. Thus, advances in cannabinoid 
receptor receptor-based therapies have the potential to treat a variety of conditions.  
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The discovery of the endocannabinoid system has opened the door for scientists all over 
the world to further explore cannabinoid receptors and ligands that activate them. However, the 
realization that this system is very complex has discouraged the development of new therapeutic 
drugs that target the cannabinoid receptors. So, it is important to develop a structure-activity 
relationship for phytocannabinoids that bind to and activate the cannabinoid receptors in order to 
help understand the important features of a core structure that give optimal activity. This will not 
only help the mystery of many related CNS diseases, but also serves as a lead for new 
therapeutics. 
In order to develop an accurate SAR, the development and establishment of in vitro 
bioassays is critical. The use of radioligand competitive binding and functional assays has been 
used for many years in the field of drug development. Full-length human recombinant cDNA for 
CB1 and CB2 were transfected into individual HEK293 cell lines and grown for use in the 
bioassays. Standardization of ligand-receptor radioligand binding and functional assays is 
required for meaningful comparisons to be made between research groups. When working with 
cannabinoids, factors such as lipophilicity, solubility, and purity are carefully investigated due 
the extreme sensitivity of the assay. Success with cannabinoid receptor bioassays requires 
optimal experimental conditions as any minimal changes may lead to major variations in binding 
affinity and functional activity. 
Targeting the cannabinoid receptors with selective compounds in critical for developing 
novel treatments that lack the unwanted side effects associated with Cannabis. It is known that 
CB1 receptors are widely spread throughout the CNS and activation of these receptors by an 
agonist leads to psychoactivity. Recent research has shown that CB2 receptors are also located 
within the brain, but are primarily peripheral. Therefore, the ability to selectively stimulate CB2 
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receptors does not cause psychoactive effects and is currently the primary target for drug 
development (Figure 5.1). 
 
Figure 5.1. Compounds from the SAR study that acted as agonists and showed the strongest 
preferential functional activity for the CB2 receptor. 
Flavonoids are common in everyday life and are consumed daily in fruits and vegetables. 
They act as powerful antioxidants. The flavonoid compounds isolated from Cannabis sativa were 
the only compounds to functionally act as inverse agonists. The ability of these compounds to 
“reverse efficacy” at both, CB1 and CB2, receptors has the potential to become a therapeutic 
O
OH
8-!-OH-"9-THC
HO
O
OH
2-dibutylamino-"8-THC
N
Cannabidivarin
HO
OH
CB1 CB2
Pain Management
Treatment for Osteoporosis
Ki=8.25nM Ki=52.99nM
Ki=3.63nM
 
 92 
 
target for the treatment of obesity and pain and inflammation associated with multiple sclerosis.  
In conclusion, in vitro bioassays involving radioligand binding and function have been a 
useful tool in the discovery of novel agents. This dissertation highlights the feasibility of 
exploring new structural scaffolds, with binding affinity and functional activity for cannabinoid 
receptors, from high potency Cannabis sativa.  
B. Future Direction 
a. Evaluation of non-Cannabis plants 
It has been concluded that natural products exhibit a vast array of pharmacological 
functions throughout the human body, and elicit these functions by acting in a manner very 
specific for their receptor. Natural products have a high chemical diversity in the compounds 
they may contain. The ecological role of natural products endows them with their biological 
function. It was the intensive study of the chemistry and pharmacology of Δ9-THC and other 
active cannabinoids from Cannabis sativa L. that led to the identification of the cannabinoid 
receptors, and ultimately the endocannabinoid system. Therefore, the combination of natural 
products and the discovery of the cannabinoid receptors offer an excellent opportunity to yield 
novel agents to treat cannabinoid receptor-based disorders.  
Fungi-derived natural products have been very successful in drug discovery in 
pharmaceutical industry for many years. However, it was not until recently that fungi-derived 
natural products were explored for the their ability to interact with cannabinoid receptors. In 
2011, twenty-nine compounds were isolated from the fungi Eurotium repens, Neocosmospora 
sp., Eupenicillium parvum, and UK-149 with the use of bioassay-guided fractionation. Of the 
twenty-nine compounds isolated, three displayed activity for the cannabinoid receptors (Figure 
5.2) (Gao 2011). If only four different fungi were evaluated and resulted with three hits for the 
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cannabinoid receptors, the field of fungi-derived natural products and their effects on 
cannabinoid receptors holds promise to the development of novel therapeutic drugs.  
 
Figure 5.2. Fungi-derived natural products that bind to the cannabinoid receptors. a) isolated 
from fungus Eurotium repens, b) and c) isolated from fungus isolated from fungus Eupenicillium 
parvum. 
Different species of fungi should be pursued to find lead compounds that activate the 
cannabinoid receptors. Furthermore, other natural products derived from sources such as plants, 
marine sponges, coral, and fish, bacteria, animals, and venom should also be evaluated. The key 
to discovering novel therapeutics and the mystery behind the mechanism of action for the 
cannabinoid receptors may lie within a natural product source.
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APPENDIX III: CHROMATOGRAPHY FOR VOLATILE OIL FRACTIONS 
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